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... Al fin y  al cabo, somos lo que hacemos para cambiar lo que somos.  
La identidad no es una pieza de museo quietecita, sino la siempre asombrosa síntesis 
de las contradicciones de cada día. 
 
... Alla fine, siamo ciò che facciamo per cambiare ciò che siamo.  
L'identità non è un pezzo da museo, ma è sempre la sorprendente sintesi delle 
contraddizioni di ogni giorno.  
(El Libro de los Abrazos-. Eduardo Galeano. 1989) 
 
 
RIASSUNTO  
Background: Il tumore alla mammella (TM) è il tumore più frequente che si 
verifica nelle donne. Dati epidemiologici hanno collegato l’assunzione degli acidi 
grassi polinsaturi omega-3 (ω-3 PUFA) con la minore incidenza di TM e diversi 
studi sperimentali hanno dimostrato gli effetti anti-proliferativi di ω-3 PUFA in 
diversi modelli di TM. L’olio di chia è ricco di acido α-linolenico (ALA, 18:3 ω-3), 
mentre l'olio di mais è ricco di acido linoleico (LA, 18:2 ω-6). L'angiogenesi è un 
processo strettamente regolato che coinvolge la proliferazione, la migrazione e la 
formazione di capillari da parte delle cellule endoteliali (CE). L’acido 
docosaesaenoico (DHA, 22:6 ω-3), un metabolita a valle dell’ALA, è stato 
dimostrato essere in grado di regolare l'angiogenesi correlatea al tumore, mentre 
l'acido arachidonico (AA, 20:4 ω-6) promuove l'angiogenesi. Inoltre, l'aspirina 
(ASA) ha effetti antineoplastici che sono mediati, almeno in parte, da metaboliti 
derivati dall’acetilazione della COX-2. Lo scopo dello studio è stato quello di 
determinare il ruolo degli ω-3 PUFA sulla crescita del un tumore alla mammella 
e, in particolare, di valutare l'effetto di metaboliti derivati dalla COX-2 acetilata in 
presenza di DHA nell'angiogenesi. 
Metodi: 40 topi BALB/c sono stati nutriti con 1) una dieta ricca di ω-3 PUFA 
contenente il 10% di olio di chia (ChO); o 2) una dieta ricca d ω-6 PUFA 
contenente il 10% d’olio mais (CO). In seguito, i topi sono stati inoculati con una 
linea di cellule tumorali (LM3) per indurre il tumore primario ed i parametri di 
crescita tumorale sono stati registrati dopo 45 giorni. Nelle sezioni di tessuto 
tumorale sono state valutate le cellule mitotiche ed apoptotiche e l'angiogenesi 
mediante immunoistochimica. Gli esperimenti in vitro sono stati condotti con 
cellule endoteliali umane (HUVECs). Le HUVECs sono state trattate con DHA o 
AA (1-100 µM) per diversi tempi in presenza o assenza di ASA (50 µM). Inoltre, 
alcuni esperimenti sono stati effettuati con 17R-HDHA (100 nM - 3 μM), un 
metabolita derivato dalla COX-2 acetilata in presenza di DHA. La produzione 
endogena di 17R-HDHA da parte delle HUVECs è stata analizzata mediante 
spettrometria di massa. La citotossicitá dei composti è stata valutata con il test 
MTT. La capacità angiogenica delle HUVECs è stata valutata utilizzando a) il 
saggio della chiusura della ferita, b) la chemiotassi in camera di di Boyden e c) la 
formazione dei capillari con il saggio di matrigel. 
Risultati: Dopo 45 giorni l'incidenza tumorale era più alta nei topi sottoposti a 
dieta con olio di mais (CO) rispetto a quelli alimentati con la dieta chia (ChO) 
(100 vs 85%, p <0.05). Il peso tumorale ed il volume del tumore, così come il 
numero delle metastasi erano più bassi nei topi che avevano ricevuto la dieta 
ChO, mentre il tempo di latenza del tumore è risultato più lungo nei topi alimentati 
con la dieta ChO. Inoltre, nel gruppo di topi sottoposti a dieta ChO sono state 
osservate un maggior numero di cellule apoptotiche, un minor numero di cellule 
mitotiche cosí come un minor numero di vasi rispetto al gruppo di controllo (CO). 
Alla luce di questi risultati in vivo, abbiamo studiato se ω-3 PUFA avevano attivitá 
anti-angiogenica diretta sulle CE umane. Non abbiamo osservato variazioni nella 
vitalità delle cellule endoteliali trattate con DHA fino a 50 µM o AA, in presenza o 
assenza di ASA per 24h, cosí come nelle cellule trattate con 17R-HDHA. La 
migrazione delle CE valutata mediante il saggio di chiusura della ferita, è 
significativamente diminuita rispetto al controllo nelle cellule pretrattate per 24 ore 
con 30 µM DHA, ma non in quelle pretrattate con 10 µM DHA. Tuttavia, è 
interessante sottolineare che 10 µM DHA in presenza di 50 µM ASA ha inibito 
significativamente la migrazione delle CE (-36%±5.4%, p<0.001) già dopo 24 ore. 
Per contro, AA in presenza o assenza di ASA non ha influenzato la migrazione 
cellulare a nessuna delle concentrazioni valutate (1-30 µM). In linea con questi 
risultati, le HUVECs trattate con DHA in presenza d’ASA ha prodotto una 
maggiore quantità di 17R-HDHA rispetto alle cellule trattate con solo DHA. 
Inoltre, il pretrattamento per 24h con 17R-HDHA (1-3 µM) ha diminuito la 
migrazione delle cellule endoteliali valutata con il test di chiusura della ferita (-
12%±4.1% and -28%±1.9%, p<0.05 e p<0.01,  rispettivamente). Inoltre, 17R-
HDHA (300 nM, 1-3 µM per 6 ore) ha ridotto la migrazione cellulare valutata in 
una camera di chemiotassi (-20%±1.4%, -30%±4.0% and -65%±3.5%, p<0.01 e 
p<0.001, rispettivamente), mentre DHA da solo non ha mostrato alcun effetto. 
Inoltre, 17R-HDHA ha diminuito la formazione di strutture capillaro-simili dopo 6 
ore. In particolare, valutando diversi parametri, si è visto che i nodi, le maglie e la 
zona delimitata dalle maglie erano significativamente più bassi nelle cellule 
trattate con 10 µM DHA in presenza di 50 µM ASA, così come in quelle cellule 
trattate con 17R-HDHA (300 nM - 3 µM). 
Conclusione: i risultati in vivo in un modello murino di tumore al seno, mettono 
in luce un ruolo degli ω-3 PUFA nella crescita tumorale. I risultati in vitro 
dimostrano che l’acetilazione della COX-2 da parte dell’aspirina porta alla 
produzione di metaboliti che potenziano gli effetti anti-angiogenici di DHA e 
possono avere un ruolo nel tumore.  
ABSTRACT 
Background: Breast cancer (BC) is the most frequent cancer occurring in 
women. Epidemiological data have linked ω-3 polyunsaturated fatty acids 
(PUFAs) consumption to lower incidence of BC and several experimental studies 
showed the anti-proliferative effects of ω-3 PUFAs in different BC models. Chia 
oil is rich in α-linolenic acid (ALA, 18:3 ω-3), while corn oil is rich in linoleic acid 
(LA, 18:2 ω-6). Angiogenesis is a tightly regulated process involving endothelial 
cells (ECs) proliferation, migration and tube formation. Docosahexaenoic acid 
(DHA, 22:6 ω-3) a downstream metabolite from ALA, has been demonstrated to 
regulate cancer-related angiogenesis, while arachidonic acid (AA, 20:4 ω-6) 
promotes angiogenesis. In addition, aspirin (ASA) has antineoplastic effects that 
are mediated at least in part by metabolites derived from acetylated COX-2. The 
study was aimed to determine a possible role of dietary ω-3 PUFAs on BC 
growth and, in particular, the effect of DHA metabolites from ASA-acetylated 
COX-2 in the angiogenic process.  
Methods: 40 BALB/c mice were fed 1) a Chia Oil (ChO)-rich (ω-3), or 2) a Corn 
Oil (CO)-rich diet (ω-6). Afterwards, mice were inoculated with mouse BC cells 
(LM3) and tumor growth parameters were recorded after 45 days. Mitotic and 
apoptotic figures, as well angiogenesis in tumor sections were assessed by 
immunohistochemistry. Human endothelial cells (ECs) were treated with DHA or 
AA (1-100 μM) for different times in the presence or absence of ASA (50 µM). 
Selected experiments were performed with 17R-HDHA (100 nM - 3µM), a DHA 
metabolite derived from acetylated COX-2. Endogenous production of 17R-
HDHA by HUVECs was analyzed by Liquid chromatography-tandem mass 
spectrometry. EC viability was analyzed with the MTT assay. The angiogenetic 
capability was evaluated using a) the wound healing assay, b) a chemotaxis 
chamber, and c) matrigel.  
Results: After 45 days tumour incidence was higher in CO-fed compared with 
ChO-fed mice (100 vs 85%, p<0.05). Tumor weight and volume as well as 
metastasis number were lower, whereas tumor latency time was longer in ChO-
fed mice. Compared to the control group, a higher number of apoptotic bodies, a 
lower number of mitosis and vessels were consistently observed in the ChO-fed 
mice group. Given these in vivo findings, we next studied whether ω-3 PUFAs 
had direct anti-angiogenic actions on human ECs. Cells were viable when treated 
with up to 50 µM DHA or AA in the presence or absence of ASA for 24h. 
Challenging the cells with 17R-HDHA for 24h did not affect cell viability. EC 
migration, as evaluated by wound healing assay, was significantly decreased in 
cells pretreated for 24h with 30 µM, but not 10 µM DHA compared to control. 
Interestingly, 10 µM DHA in the presence of 50 µM ASA significantly inhibited 
ECs migration (-36%±5.4%, p<0.001) already after 24h. By contrast, AA did not 
affect EC migration at any concentration tested (1-30 μM) in the presence or 
absence of ASA. Consistently, ECs treated with DHA+ASA produced higher 
amounts of 17R-HDHA with respect to cells treated with DHA alone. 
Pretreatment with 17R-HDHA (1-3 µM, 24h) decreased EC migration (-
12%±4.1% and -28%±1.9%, p<0.05 and p<0.01, respectively) evaluated by the 
wound healing assay. Additionally, 17R-HDHA (300 nM, 1 or 3 µM, 6h) reduced 
EC migration as evaluated in a micro chemotaxis chamber (-20%±1.4%, -
30%±4.0% and -65%±3.5%, p<0.01 and p<0.001, respectively), while DHA did 
not show any effect. Furthermore, 17R-HDHA inhibited EC tube formation after a 
6h treatment. In particular, nodes, meshes and mesh area were significantly 
lower in 10 µM DHA-treated cells in the presence of 50 µM ASA, as well as in 
17R-HDHA (300 nM-3 µM)-treated cells. 
Conclusion: In vivo and ex vivo data point to a central role of ω-3 PUFAs in BC 
growth. In vitro data demonstrate that aspirin-acetylated COX-2 enhances the 
anti-angiogenic effects of DHA and may have a role in the setting of tumors.  
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1. INTRODUCTION 
1.1. Cancer 
 Cancer arises through the accumulation of molecular changes that 
together allow cells to grow in an uncontrolled manner. Many factors contribute to 
this process, including hereditary genetic mutations and environmental hazards 
(Weinberg, 2013). The most common human cancers arise from epithelia and are 
called carcinomas. These tumors are responsible for more than 80% of the 
cancer-related deaths in the Western world. Included among the carcinomas are 
tumors arising from the epithelial cell layers of the gastrointestinal tract -which 
includes mouth, esophagus, stomach, and small and large intestines- as well as 
the skin, mammary gland, pancreas, lung, liver, ovary, uterus, prostate, 
gallbladder, and urinary bladder (Weinberg, 2013). 
 Cancer is defined as a polygenic and multifactorial disease where an 
interplay of factors may prevent or promote the disease. Mammalian cells have 
multiple safeguards to protect them against the potentially lethal effects of cancer 
gene mutations, and only when several genes are defective does an invasive 
cancer develop. Thus it is best to think of mutated cancer genes as contributing 
to, rather than causing, cancer. Cancer development involves multiple mutations 
within several key genes, including mutations in proto-oncogenes, tumor 
suppressor genes, and DNA repair genes. The process of accumulating 
mutations in several genes takes many years, and this is why cancer is more 
frequently seen in older individuals (Vogelstein and Kinzler 2004). Besides 
genetic influence, most adult cancers are caused mainly by environmental 
factors. This means that most cancers are at least in theory preventable. Among 
important causes of cancer are food and nutrition, physical activity and body 
composition (Rosato et al, 2013). 
 
1.1.1. Cancer epidemiology: prevalence, incidence and mortality trends.  
 Cancer is the leading cause of mortality worldwide. According to WHO 
estimates for 2011 cancer causes more deaths than all coronary heart disease or 
all strokes. Indeed, 14.1 million new cancer cases (incidence), 8.2 million cancer 
deaths occurred in 2012 worldwide and 32.6 million men and women still alive in 
2012, up to five years after their diagnosis (Ferlay et al, 2014). In Europe, more 
than 3.4 million new cases of cancer (excluding non-melanoma skin cancer) were 
diagnosed in 2012. The commonest cancers were those of breast, large bowel, 
prostate and lung, all of which represented more than 1.7 million cases annually. 
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The cancer with the largest number of incident and prevalent cases was breast 
cancer, while by far the largest number of deaths was due to lung cancer 
(Steliarova-Foucher, 2015). 
 
1.1.2. Breast cancer epidemiology: prevalence, incidence and mortality trends. 
 Breast cancer (BC), the most frequently occurring cancer in women, is a 
major public health problem, with 1384155 estimated new cases worldwide with 
nearly 459000 related deaths. It is alarming to note that GLOBOCAN statistics for 
2012 showed that approximately 1.7 million women were diagnosed with breast 
cancer in that year, with 522000 related deaths suggesting an increase in breast 
cancer incidence and related mortality by nearly 18% from 2008 (Tao et al, 
2014). The incidence and mortality rates of breast cancer vary considerably 
across countries and regions, with a four to five-fold variation in incidence 
between different geographical areas. Rates are highest in Europe and North 
America and lowest in Asia (Iwasaki and Tsugane 2011).  
 
1.1.3. Breast cancer risk factors 
 Besides genetic predisposition, scientific evidence suggests that age, 
hormone status, certain reproductive choices as well as life style factors such as 
diet, obesity and lack of physical activity, can modify the risk of breast cancer 
(Tumas et al, 2014).  
 Genetics: Mutations that predispose to breast cancer have been 
identified. These include mutations in the genes BRCA1 (breast cancer 1), 
BRCA2 (breast cancer 2), p53 (p53 tumor suppressor), PTEN (phosphatase and 
tensin homolog), and ATM (ataxia-telangiectasia mutated). Mutations in BRCA1 
and BRCA2 can cause a high risk of breast cancer. Most studies on familial risk 
of breast cancer have found about two-fold relative risks for first-degree relatives 
(mothers, sisters, daughters) of affected patients. With affected second-degree 
relatives (grandmothers, aunts, grand-daughters), there is a lesser increase in 
risk (Key et al, 2001). 
 Age: The incidence of breast cancer increases rapidly with age during the 
reproductive years and then increases at a slower rate after about age 50 years, 
the average age at menopause (Key et al, 2001). 
 Hormone status: Hormones play an important role in breast cancer 
progression because they modulate the structure and growth of epithelial tumor 
cells. The epidemiologic evidence has consistently supported a positive 
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relationship between circulating estrogen levels and postmenopausal breast 
cancer risk, with a magnitude of association ranging from 1.4 (95% CI: 0.9–2.4) 
to 6.4 (95% CI: 2.8–14.9). All studies conducted to date have reported positive 
relationships, with seven of the nine individual studies and the initial pooled 
analysis reporting borderline or statistically significant positive associations that 
are stronger among the subset of women with estrogen receptor positive (ER+) 
tumors, which further establishes the role of endogenous estrogens in the 
etiology of postmenopausal breast cancer. Compared to postmenopausal 
women, data evaluating the relationship between endogenous estrogens and 
premenopausal breast cancer risk are more limited and less consistent. Prior 
studies have been limited by small case numbers and complicated by the large 
variations in estrogens and progesterone that occur during the menstrual cycle. 
Although the association for the doubling of estradiol levels ranged from 0.6 (95% 
CI: 0.2–1.4) to 1.8 (95% CI: 97 0.9–3.7), most studies have observed a positive 
relationship, which is qualitatively similar but weaker in magnitude when 
compared to the relationship in postmenopausal women. Furthermore, in a recent 
pooled analysis of seven prospective studies that evaluated sex hormones and 
risk of premenopausal breast cancer specifically, circulating estradiol levels were 
positively associated with breast cancer (OR for doubling in concentration of 
estradiol, 1.2, 95% CI: 1.1–1.4) (Brown and Hankinson, 2015; Key et al, 2002). In 
premenopausal women (before age 50) with breast cancer diagnosis, besides 
estradiol, estrone, androstenedione, DHEAS (didehydroepiandrosterone) and 
testosterone circulating concentrations were positively associated with breast 
cancer risk, whereas luteal phase progesterone and SHBG (sex hormone binding 
globulin) were not associated with risk (Key et al, 2013). Similarly to what 
observed in premenopausal women, a number of different sex hormones such as 
testosterone, DHEAS, and SHBG measured up to 16-20 years before breast 
cancer diagnosis were significantly associated with risk of postmenopausal 
breast cancer among women not using postmenopausal hormone therapy 
(Zhang et al, 2013). 
 Further, reproductive and hormonal risk factors such as early age at 
menarche, late age at menopause, postmenopausal hormone therapy, oral 
contraceptives use, high postmenopausal body-mass index, late childbearing and 
no-breastfeeding practice all of which contribute to a greater lifetime exposure to 
estrogen, have been linked to an increased risk of most of gynecological cancers 
such as breast cancer.  
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 Menarche and the menstrual cycle: The older a woman is when she 
begins menstruating, the lower her risk of breast cancer. For each 1-year delay in 
menarche, the risk decreases by around 5%. There is also evidence that, 
although age at menarche is related to breast cancer risk at all ages, the effect 
may be stronger in younger (premenopausal) women (Key et al, 2001). 
 Menopause: Women who experience menopause at a late age are at a 
higher risk of breast cancer than those who cease menstruating earlier, with risk 
increasing by about 3% for each year older at menopause. The magnitude of this 
effect is similar whether menopause occurs naturally or as a result of bilateral 
oophorectomy. The protective effect of menopause can be seen in the slowing in 
the rate of increase in breast-cancer incidence with age that occurs at around 
age 50. Thus, premenopausal women are at higher risk of breast cancer than 
postmenopausal women of the same age, and peri-menopausal women are at 
intermediate risk (Key et al, 2001).  
 Postmenopausal body mass-index: In postmenopausal women, obesity 
increases the risk of breast cancer; risk is about 50% higher in obese women 
(body mass index >30 kg/m2) than in lean women (body mass index 20 kg/m2). 
This association is not observed in premenopausal women, among whom some, 
but not all, studies have observed that risk is slightly lower in obese women than 
in women of normal weight (Key et al, 2001). 
 Exogenous hormones: The use of oral contraceptives increased the risk 
of breast cancer by around 25% in current users of combined oral contraceptives, 
but the excess risk falls after cessation of use, such that 10 or more years after 
use stops, no significant increase in risk is evident. Risk does not vary 
significantly with duration of use, nor does the effect of combined oral 
contraceptives vary significantly according to other risk factors. The effect on risk 
of breast cancer does not vary with the type of estrogen or progestagen used. 
Although data on progestagen only oral contraceptives are limited, their effects 
seem to be broadly similar to those of combined preparations. The 
postmenopausal hormone therapy was also studied. Hormonal therapy use for 
the menopause occurs at a time when a woman is at high and increasing 
background risk of breast cancer. Current users of hormonal therapy for the 
menopause are at higher risk of breast cancer than women who have never used 
these preparations (Key et al, 2001). 
 Reproductive choices: Not bearing children and late (over 30) first 
pregnancy are recognized to increase the risk of breast cancer. Childbearing 
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seems to have a dual effect on breast cancer risk; it is increased in the period 
immediately after a birth, but this excess risk gradually diminishes and, in the 
longer term, the effect of a birth is to protect against the disease. Compared with 
nulliparous women, who have had at least one full-term pregnancy have around 
a 25% reduction in breast cancer risk. Furthermore, increasing protection is seen 
with increasing numbers of full-term pregnancies, such that women with five or 
more children have about half the risk of nulliparous women (Key et al, 2001). 
 Breastfeeding practice: Lactation is associated with increased 
differentiation of breast cells and with lower exposure to endogenous sex 
hormones during amenorrhea accompanying lactation. In addition, the strong 
exfoliation of breast tissue during lactation, and the massive epithelial apoptosis 
at the end of lactation, could decrease risk by elimination of cells with potential 
DNA damage. Women with breast cancer had, on average, fewer births than did 
controls (2.2 vs 2.6). Furthermore, fewer parous women with cancer than parous 
controls had ever breastfed (71% vs 79%), and their average lifetime duration of 
breastfeeding was shorter (9.8 vs 15.6 months). The relative risk of breast cancer 
decreased by 4.3% (95%, CI 2.9-5.8) after 12 months of breastfeeding. The size 
of the decline in the relative risk of breast cancer associated with breastfeeding 
did not differ significantly for women in developed and developing countries, and 
did not vary significantly by age, menopausal status, ethnic origin, the number of 
births a woman had, her age when her first child was born, or any of nine other 
personal characteristics examined (Collaborative Group on Hormonal Factors in 
Breast Cancer, 2002).  
 Lifestyle: Moderate physical activity is associated with a lower risk of 
breast cancer. The size of the effect of high physical activity has varied widely 
between studies, but a typical result is a reduction in risk of around 30% in 
association with a few hours per week of vigorous activity versus none (Key TJ et 
al, 2001). Several studies showed that between 80 and 90% of cancers are 
related to environmental factors and it is estimated that 35% are related to dietary 
factors (WCRF, 2007). The observation that breast cancer rates are much higher 
in countries with high-fat diets than in countries where fat intake is much lower, 
led to the hypothesis that high-fat diets increase breast cancer risk. More recent 
studies have looked at other possible dietary determinants of risk, such as 
consumption of meat, fiber, fruit and vegetables. There may be a moderate 
protective effect for a high consumption of vegetables, but results for meat, fiber, 
and fruit have been inconsistent, and breast cancer risk has not been shown to 
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be lower in vegetarians than in non-vegetarians in more developed countries 
(Key et al, 2001). In a large multicenter Italian case-control study, breast cancer 
risk was directly related to cereals, and hence available carbohydrates, and 
inversely related to vegetables and polyunsaturated fatty acids (Rosato et al, 
2013).  
 
1.1.4. Carcinogenesis: The six hallmark capabilities of cancer cells. 
 Normal cells evolve progressively to a neoplastic state (phenotype). 
Carcinogenesis is understood as a biological process occurring at multi-stages 
continuously. The hallmarks of cancer comprise specific capabilities acquired 
during the multistep development of human tumors. Indeed it is well known that, 
tumor cells develop self-sufficiency in growth signaling, insensitivity to anti-growth 
signals, limitless replicative potential and the capability to evading apoptosis that 
allow tumor growth. Moreover, the tumor-associated neovasculature, generated 
by the process of angiogenesis, as well as the activation of the processes of 
invasion and metastasis, allow carcinomas progress to higher pathological 
grades of malignancy (Hanahan and Weinberg, 2000; Hanahan and Weinberg, 
2011). 
 Self-sufficiency in growth signaling: It was the first tumor-specific 
capability to be clearly defined by cancer researchers. Normal cells require 
mitogenic growth signals before they can move from a quiescent state into an 
active proliferative state. These signals are transmitted into the cell by 
transmembrane receptors that bind distinctive classes of signaling molecules: 
diffusible growth factors, extracellular matrix components, and cell-to-cell 
adhesion/interaction molecules. Many of the oncogenes in cancer act by 
mimicking normal growth signaling in one way or another. Three common 
molecular strategies for achieving autonomy are evident, involving alteration of 
extracellular growth signals, transcellular transducers of those signals, or 
intracellular circuits that translate those signals into action. While most soluble 
mitogenic growth factors (GFs) are made by one cell type in order to stimulate 
proliferation of another -the process of heterotypic signaling- many cancer cells 
acquire the ability to synthesize GFs to which they are responsive, creating a 
positive feedback signaling loop often termed autocrine stimulation (Fedi et al, 
1997). Clearly, the manufacture of a GF by a cancer cell obviates dependence on 
GFs from other cells within the tissue. The cell surface receptors that transduce 
growth stimulatory signals into the cell interior are themselves targets of 
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deregulation during tumor pathogenesis. Receptor overexpression may enable 
the cancer cells to become hyperesponsive to ambient levels of GFs that 
normally would not trigger proliferation (Hanahan and Weinberg, 2011).  
 Insensitivity to antigrowth signals: Within a normal tissue, multiple anti-
proliferative signals operate to maintain cellular quiescence and tissue 
homeostasis; these signals include both, soluble growth inhibitors and 
immobilized inhibitors embedded in the extracellular matrix and on the surfaces 
of nearby cells. These growth inhibitory signals, like their positively acting 
counterparts, are received by transmembrane cell surface receptors coupled to 
intracellular signaling circuits. Antigrowth signals can block proliferation by two 
distinct mechanisms. Cells may be forced out of the active proliferative cycle into 
the quiescent (G0) state from which they may reemerge on some future occasion 
when extracellular signals permit. Alternatively, cells may be induced to 
permanently relinquish their proliferative potential by being induced to enter into 
post-mitotic states. Much of the circuitry that enables normal cells to respond to 
antigrowth signals is associated with the cell cycle clock. Incipient cancer cells 
must evade these anti-proliferative signals, which depend on the actions of tumor 
suppressor genes, if they are to prosper (Weinberg, 1995).  
In breast cancer, the cell traits characterizing proliferation-related markers 
and insensitivity to growth factors inhibitor signals involve deregulated expression 
of cyclins, cyclin-dependent kinases (CDK) and CDK inhibitors (CDKIs) and 
oncogene products, such as ras, c-myc, steroid hormone receptors and growth 
factor receptors, e.g. members of the HER/erbB family (Daidone et al, 2014). 
 Limitless replicative potential: Many and perhaps all types of mammalian 
cells carry an intrinsic, cell-autonomous program that limits their multiplication. 
Cells in culture have a finite replicative potential. Once such cell populations have 
progresses through a certain number of doublings, they stop growing a process 
termed senescence. In cancer cells, this program must be disrupted in order for a 
clone of cells to expand to a size that constitutes a macroscopic. Most types of 
tumor cells that are propagated in culture appear to be immortalized, suggesting 
limitless replicative potential is a phenotype that was acquired in vivo during 
tumor progression and was essential for the development of their malignant 
growth state (Hanahan and Weinberg, 2011).  
 Evading apoptosis: In principle, the resulting deregulated proliferation 
program should suffice to enable the generation of the vast cell populations that 
constitute macroscopic tumors. However, the ability of tumor cell populations to 
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expand in number is determined not only by the rate of cell proliferation but also 
by the rate of cell attrition. Programmed cell death -apoptosis- represents a major 
source of this attrition. The evidence is mounting, principally from studies in 
mouse models and cultured cells, as well as from descriptive analyses of 
biopsied stages in human carcinogenesis, that acquired resistance toward 
apoptosis is a hallmark of most and perhaps all types of cancers including breast 
cancer. The apoptotic machinery can be divided into two classes of components, 
sensors and effectors. The sensors are responsible for monitoring the 
extracellular and intracellular environment for conditions of normality or 
abnormality that influence whether a cell should live or die. These signals 
regulate the second class of components, which function as effectors of apoptotic 
death (Wyllie, 1980). Resistance to apoptosis can be acquired by cancer cells 
through a variety of strategies. The most common is the loss of p53 tumor 
suppressor function, which eliminates this critical damage sensor from the 
apoptosis-inducing circuitry. Alternatively, tumors may achieve similar ends by 
increasing expression of anti-apoptotic regulators (Bcl-2, Bcl-xL) or of survival 
signals (Igf1/2), by downregulating pro-apoptotic factors (Bax, Bim, Puma), or by 
short circuiting the extrinsic ligand-induced death pathway. The multiplicity of 
apoptosis avoiding mechanisms presumably reflects the diversity of apoptosis 
inducing signals that cancer cell populations encounter during their evolution to 
the malignant state (Hanahan and Weinberg, 2011). Apoptosis related proteins, 
such as bcl-2 (anti-apoptotic) and bax (pro-apoptotic), have been extensively 
studied in breast cancer as prognostic and predictive markers (Daidone et al, 
2014). 
 Invasion and metastasis: Sooner or later during the development of most 
types of human cancer, primary tumor masses spawn pioneer cells that move 
out, invade adjacent tissues, and then travel to distant sites where they may 
succeed in founding new colonies. These distant settlements of tumor cells 
metastases are the cause of 90% of human cancer death. The capability for 
invasion and metastasis enables cancer cells to escape the primary tumor mass 
and colonize new terrain in the body where at least initially, nutrients and space 
are not limiting. The multistep process of invasion and metastasis has been 
schematized as a sequence of discrete steps, often termed the invasion 
metastasis cascade. This depiction envisions a succession of cell-biologic 
changes, beginning with local invasion, then intravasation by cancer cells into 
nearby blood and lymphatic vessels, transit of cancer cells through the lymphatic 
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and hematogenous systems, followed by escape of cancer cells from the lumina 
of such vessels into the parenchyma of distant tissues (extravasation), the 
formation of small nodules of cancer cells (micrometastases), and finally the 
growth of micrometastatic lesions into macroscopic tumors, this last step being 
termed colonization (Talmadge et al, 2010). Invasion and metastasis are 
exceedingly complex processes, and their genetic and biochemical determinants 
remain incompletely understood. At the mechanistic level, they are a closely 
allied process, which justifies their association with one another as one general 
capability of cancer cells. Both utilize similar operational strategies, involving 
changes in the physical coupling of cells to their microenvironment and activation 
of extracellular proteases. The activation of extracellular proteases and the 
altered binding specificities of cadherins, CAMs, and integrins are clearly central 
to the acquisition of invasiveness and metastatic ability (Hanahan and Weinberg, 
2011). 
 Angiogenesis: The oxygen and nutrients supplied by the vasculature are 
crucial for cell function and survival, obligating virtually all cells in a tissue to 
reside within 100µm of a capillary blood vessel. During organogenesis, this 
closeness is ensured by coordinated growth of vessels and parenchyma. Once a 
tissue is formed, the growth of new blood vessels -the process of angiogenesis- 
is transitory and carefully regulated. Because of this dependence on nearby 
capillaries, it would seem plausible that proliferating cells within a tissue would 
have an intrinsic ability to encourage blood vessel growth. During tumor 
progression, an ‘‘angiogenic switch’’ is almost always activated and remains on 
causing normally quiescent vasculature to continually sprout new vessels that 
help sustain the expansion of neoplastic growths (Hanahan and Folkman, 1996). 
A compelling body of evidence indicates that the angiogenic switch is governed 
by countervailing factors that either induce or oppose angiogenesis (Baeriswyl 
and Christofari, 2009). This process will be described in details in the next 
section.  
As in the case of other solid tumors, invasion and metastasis of breast 
cancer depends on activation of neoangiogenesis and on modifications of the 
extracellular matrix. In recent years many papers have been published on these 
topics, reporting suggestive data for a significant association between 
overexpression of markers related to or indicative of these functions and disease 
progression. In particular, hypervascularisation and surrogate markers related to 
the formation of new blood vessels, such as CD31 and vascular endothelial 
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growth factor (VEGF), have been proved to be associated with new disease 
manifestation (Daidone et al, 2014). 
Overall, the hallmarks of cancer comprise six biological capabilities 
acquired during the multistep development of human tumors, which have 
provided a useful conceptual framework for understanding the complex biology of 
cancer and will increasingly affect the development of new means to treat human 
cancer. 
 
 
Figure 1.1: Hallmarks of cancers represented by the acquired capabilities of 
cancer cells (Hanahan and Weinberg et al, 2000). 
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1.2. Angiogenesis 
 Blood vessels supply oxygen and nutrients and provide gateways for 
immune surveillance. Endothelial cells (ECs) line the inner surface of vessels to 
support tissue growth and repair. As this network nourishes all tissues, it is not 
surprising that structural or functional vessel abnormalities contribute to many 
diseases. 
 Angiogenesis is both a physiological and pathological process, which 
leads to the formation of new blood vessels. Physiologically the process of 
angiogenesis begins at implantation, and during placental and embryonic 
development. In later life the process is prominent in the healing of wounds, 
osteogenesis, as well as in ovulatory-related and non-ovulatory-related 
reproductive processes. Furthermore, pathological angiogenesis is related to 
inflammatory disorders, pulmonary hypertension, blinding eye disease and the 
development of both benign and malignant tumors (Potente et al, 2011). In 1971 
Folkman hypothesized that tumor growth is dependent on angiogenesis and 
subsequently experimental work demonstrated that for a tumor to grow beyond a 
size of 1-2 mm3 a substantial new blood supply must develop to support the 
increasing metabolic requirements. In addition, in the setting of the tumor, 
vessels are also used as routes for tumor cells to metastasize (Folkman, 1971). 
 
1.2.1. Factors affecting angiogenesis 
 Angiogenesis is subject to a complex control system with the involvement 
of both pro-angiogenic and anti-angiogenic factors. Under physiological 
conditions, angiogenesis is tightly controlled by an angiogenic balance, i.e., a 
physiological balance between stimulatory and inhibitory signals for blood vessel 
growth. A switch to the angiogenic phenotype depends on a local change in the 
balance between angiogenic stimulators and inhibitors, as a consequence of 
variation in tissue oxygen tension or endothelial damage (Arnal et al, 2010).  
 The stimuli that trigger angiogenesis such as hypoxia, inflammation, 
mechanical forces (shear stress/strech) and exercise initiate the production of 
growth factors (Milkiewicz et al, 2005). Besides growth factors, hormones such as 
estrogens, prolactin, insulin and melatonin also influence angiogenesis. In 
addition, neurotransmitters such as nicotine (nicotinic receptor) and 
catecholamine have been shown to modulate various aspects of angiogenesis 
acting on specific receptors (Mousa et al, 2013). Dietary factors also may act as 
an important component in regulating the angiogenic switch as they have an 
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important impact on cellular physiology and homeostasis, and hence could 
influence the equilibrium between anti- and pro-angiogenic factors (Bhat and 
Singh, 2008). Growth factors have both stimulatory and inhibitory roles within 
sprouting angiogenesis, the most investigated compound being vascular 
endothelial growth factor (VEGF) and fibroblast growth factor (FGF), which are 
known to be potent stimulators of angiogenesis. Many others molecules such as 
platelet derived growth factor (PDGF), epidermal growth factor (EGF), 
angiopoietins (Ang), and TIE-receptors, Eph receptors and ephrins, hepatocyte 
growth factor (HGF), thymidine phosphorylase (TP), neuropeptide Y (NPY), 
platelet factor 4 (PF4) are considered the main mediators involved in 
angiogenesis (Bouȧs et al, 2004). In contrast, there are a number of angiogenesis 
inhibitor molecules such as angiostatin, endostatin, tissue inhibitors of 
metalloproteinases (TIMPs), which serve to downregulate the angiogenesis 
response giving a negative feedback in vessel sprouting (Milkiewicz et al, 2005; 
Boosani and Sudhakar, 2011).  
 Endocrine hormones -steroids and peptides small molecules- are able to 
regulate angiogenesis. Most of these hormones appear to exert their effect on 
blood vessels only in specific tissues, but the angiogenic properties of these 
substances have not been systematically studied in tissues other than those that 
are classical targets (Mousa et al, 2013). 
 Estrogen and progesterone contribute to uterine angiogenesis in the 
menstrual cycle (Matsubara and Matsubara, 2012). Besides its role in menstrual 
cycle, estrogens have also been described to promote re-endothelization after 
arterial injury. The mechanisms involved in the pro-angiogenic effects of 
estrogens are probably multifactorial. Importantly, estrogen induces three of the 
most important pro-angiogenic factors: FGF-2, VEGF, and nitric oxide (NO). All 
these molecules could contribute to the neuro and cardioprotective effects of 
estrogens observed in models of ischemia/reperfusion injury (Arnal et al, 2010). 
In contrast, the endogenous metabolite of estrogen, 2-methoxyestradiol, has 
been described as a potent inhibitor of endothelial cell proliferation, migration and 
angiogenesis in vitro (Albini et al, 2010). Estrogen plays an important role in the 
development and growth of the mammary gland during puberty, pregnancy and 
lactation. In the setting of estrogen-sensitive tumors, estrogens modulate cell 
proliferation, adhesion, migration, and invasion. In addition, estrogens promote 
the formation of new blood vessels within the tumor mass, hence suggesting that 
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these steroids elicit a stimulatory role not only in cancer cells but also in 
components of the surrounding stroma (de Francesco et al, 2014).  
 Besides estrogen, prolactin, the lactation stimulating hormone that almost 
exclusively acts on the mammary gland is angiogenic in certain tissues (Reuwer 
et al, 2012). Prolactin can be proteolytically cleaved giving rise to angiostatic 
peptides with a strong anti-angiogenic activity, mediated by the inhibition of MAP-
kinases (Albini et al, 2010). It has been suggested that chronic hyperinsulinemia 
associated with insulin resistance plays a role in breast cancer etiology and 
progression (Rostoker et al, 2015). In line with this, insulin promotes 
angiogenesis, at least in part via local VEGF production and stimulation of 
endothelial cell proliferation (Cubbon et al, 2012). In addition to female hormones 
and insulin, melatonin the main secretory product of the pineal gland, has been 
described to have a role in breast cancer angiogenesis. In particular, melatonin 
inhibits VEGF production in human breast cancer cells (Alvarez-Garcia et al, 
2013). 
 Other factors besides hormones might affect tumor angiogenesis. In the 
past years, food and dietary components have been identified as modulators of 
angiogenesis. This is the case of genistein, contained in soy, epigallocatechin 3-
gallate, abundant in green tea, resveratrol, contained in wine, kahweol, present in 
unfiltered coffee, oleocanthal and hydroxytyrosol, two constituents of virgin extra 
olive oil, carnosol and carnosic acid, two major components of rosemary extracts 
(Medina and Quesada, 2014). A particular attention has been devoted to the role 
of fatty acids (FAs), particularly to polyunsaturated fatty acids (PUFAs) in the 
setting of tumor angiogenesis. 
It is well established that the metabolites of Ȧ-6 and Ȧ-3 PUFAs, which 
must be obtained through the diet have differential effects on cellular processes. 
Ȧ-6 PUFAs-derived metabolites promote angiogenesis by increasing growth 
factor expression whereas Ȧ-3 PUFAs have anti-angiogenic and anti-tumor 
properties (Kang and Liu, 2013). Ȧ-3 PUFAs, principally from fish oil, modulate 
angiogenesis by suppressing downstream metabolites of arachidonic acid (AA), 
an Ȧ-6 PUFAs (Kang and Liu, 2013). In particular, eicosapentaenoic acid (EPA) 
and docosahexaenoic acid (DHA) two Ȧ-3 PUFAs, have potent anti-angiogenic 
effects inhibiting production of many important angiogenic mediators such as 
VEGF, PDGF, cyclo-oxygenase 2 (COX-2)-derived prostaglandin-E2 (PGE2) 
(Spencer et al, 2009). The role of fatty acids in angiogenesis will be further 
described (see on page 39). 
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1.2.2. Phases of angiogenesis 
 The formation of new vessels, i.e. angiogenesis, starts from abluminal 
sprouting from preexisting vessel. The angiogenesis sprouting steps can roughly 
be divided into a permeability phase, a proliferation, proteolysis and migration 
phase and a stabilization maturation phase (lumen formation phase) (Figure 1.2). 
This process is initiated by activation of endothelial cells by growth factors, 
mechanical and/or inflammatory stimuli.  
 First of all, permeability (1) across the endothelial cell layer increases, and 
this is followed by the proliferation of endothelial cells (2). Subsequently, 
proteolysis (3) of basement membrane components (controlled mainly by MMPs) 
enables sprouting of the endothelial cell into the interstitial space. After that, a 
continued coordination of cell adhesion and cytoskeletal remodeling components 
provide directional migration of the sprouting (4) endothelial cells. Eventually, the 
new sprout forms a lumen (5) by the process of intracellular vacuolar fusion or by 
stabilization of several cells around a central lumen. A new lateral branch will be 
formed when the sprout anastomosis with a pre-existing capillary. Alternatively, 
circulating endothelial progenitor cells (EPCs) (A) may contribute to the sprout 
process, adhering (B) to the activated endothelial cell, extravasating (C) through 
the endothelial cell layer, and clustering (D) within the intersitium. Some of these 
EPCs will integrate (E) into the sprout and comprise a portion of the newly formed 
capillary while others may remain as perivascular cells (Milkiewicz et al, 2005). 
 
 
Figure 1.2: Phases of sprouting angiogenesis (Milkiewicz, 2005). 
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The regulation of the process of abluminal sprouting involves specific 
molecules, which finely tune the angiogenesis sprouting steps.  
 Permeability: Angiogenic stimuli cause increased endothelial cell 
permeability through dissolution of adherens junctions responsible for cell–cell 
contacts. Release of endothelial cell junctions also promotes a pro-migratory 
phenotype. Endothelial permeability is regulated by adherens junctions, which 
are formed primarily through extracellular homophilic interactions between 
vascular endothelial (VE)-cadherins, with intracellular stabilization to the actin 
cytoskeleton via interactions with ȕ-catenin and α-catenin (Corada et al, 1999; 
Dejana, 2004). EGF and HGF receptor tyrosine kinases both induce tyrosine 
phosphorylation of ȕ-catenin and this correlates with decreased cell–cell 
adhesion and increased cell migration (Hoschuetzky et al, 1994).  
 Proliferation: Endothelial cell proliferation occurs early in angiogenesis, 
and continues as the new capillary sprout elongates. Activation of P13K/Akt 
promotes endothelial cell survival and proliferation through modulation of 
numerous cell cycle regulators, including cyclinD1, p27 and Bcl-X2 (Pages et al, 
β000). Interestingly, ȕ-catenin may dissociate from the adherens junction 
complexes, and translocate to the nucleus where it binds to T-Cell Factor, 
through which it acts as a transcriptional co-activator of numerous gene targets 
including proliferation mediators such as cyclinD1 and c-myc (Ben Ze’ev et al, 
β000). Nuclear accumulation of ȕ-catenin occurs with VEGF stimulation, and thus 
it may serve to couple initial events in growth factor triggered permeability with 
subsequent activation of cellular proliferation and proteolysis.  
 Proteolysis: The critical role that basement membrane degradation plays 
in the process of abluminal sprouting has been recognized for many years. 
Proteolysis is necessary to promote endothelial cell invasion into the surrounding 
interstitial matrix. Matrix metalloproteinases (MMPs) are zinc dependent 
proteases capable of degrading numerous matrix components. Several different 
MMPs are produced by endothelial cells and are implicated strongly in the 
process of capillary sprouting (Haas et al, 2005). Animal studies demonstrate that 
MMP inhibition can suppress both physiological (exercise-induced) angiogenesis 
and capillary growth within tumors, suggesting that regulation of MMP activity is a 
therapeutic target (Guedez et al, 2003). In addition to MMP, Plasmin is an active 
tryptic protease derived from proteolysis of plasminogen by tissue or urokinase 
plasminogen activators (tPA or uPA). This activation is facilitated by interaction of 
plasminogen and PA with the cell surface-localized receptor uPAR. uPA and 
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uPAR are upregulated by bFGF and VEGF stimulation and by hypoxic conditions 
(Pepper, 2001).  
 Migration: Cellular attachments to matrix molecules and the intracellular 
modulation of cytoskeletal components both determine the migratory properties 
of endothelial cells. Integrins play a prominent role in cell-matrix adhesion. 
Expression of integrins αvȕγ and αvȕ5 is increased in proliferating endothelial 
cells, and by bFGF and VEGF stimulation (Nisato et al, 2003). Antagonists that 
disrupt endogenous matrix-integrin interactions can inhibit angiogenesis in 
various model systems (Brooks et al, 1994; Hammes et al, 1996; Nisato et al, 
2003). Endothelial cell migration during angiogenesis is the integrated resultant 
of these 3 mechanisms. Typically, chemotaxis of endothelial cells is driven by 
growth factors such as VEGF and basic fibroblast growth factor (bFGF), whereas 
haptotaxis is associated with increased endothelial cell migration activated in 
response to integrins binding to ECM component. Because of their location at the 
inner face of blood vessels, endothelial cells are constantly in contact with shear 
stress, which contributes to activate migratory pathways. In fact, there is now 
accumulating evidence that fluid shear stress initiates mechanotaxis and 
modulates the various steps of migration (Lamalice et al, 2007). 
 Lumen formation and stabilization: The lumen of a blood vessel is 
essential for providing blood to any given tissues. In the vascular system, lumen 
formation involves a complex molecular mechanism composed of endothelial cell 
repulsion at the cell-cell contacts within the endothelial cell cords, junctional 
rearrangement, and endothelial cell shape change (Ribatti et al, 2012). It occurs 
as the sprout forms a multicellular structure because capillary sprouts generally 
are composed of one or two cells. These sprouts may form a lumen by 
intracellular canalization, which occurs through fusion of cytoplasmic vesicles, or 
by the alternative process of intercellular canalization, in which a lumen is created 
by the membrane apposition of two different cells (Egginton and Gerritsen, 2003). 
Stabilization of the nascent capillaries is a significant step in completion of the 
angiogenic process. The new capillary channel forms an anastomosis with a pre-
existing capillary, creating a new patent capillary. The final stage requires 
stabilization of the capillary through the construction of basement membrane, 
adherens junctions and cessation of endothelial cell activation. This in part is 
accomplished through the production of factors that promote a differentiated and 
stable capillary morphology. Angiopoietin-1 (Ang-1) is produced constitutively in 
most adult tissues, and it binds and activates the endothelial cell specific tyrosine 
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kinase receptor (Tie-2). Tie-2 activation promotes endothelial quiescence through 
the MAPK and PI3K/Akt pathways that induce cell survival, but not endothelial 
cell proliferation (Peters et al, 2004). Placental derived growth factor (PDGF) may 
assist in the stabilization process. PDGF has a high affinity for VEGFR-1, and 
through activation of VEGFR-1 on pericytes or smooth muscle cells, stimulates 
increased coverage and stabilization of capillaries, and the formation of larger 
diameter collaterals (Autiero et al, 2003). 
 The knowledge of the specific steps and molecules involved in the 
angiogenic process is of paramount importance for the future development of 
novel therapeutic strategies targeting angiogenesis.  
 
1.2.3. Antiangiogenic drugs in tumors 
 Antiangiogenic therapy has become a mainstay of cancer therapeutics, 
but clinical responses are generally active for short-term owing to the 
development of secondary resistance. A summary of the main drugs and 
pharmacological targets of angiogenesis is presented in Table 1.1 (Quintieri et al, 
2014). 
 Currently, most of the FDA approved drugs, as well as those in phase III 
clinical trials target a single pro-angiogenic protein (Presta et al, 2009). In 
particular, the identification of VEGF as a key driver of the angiogenic process 
has converted the VEGF/VEGF receptor (VEGFR) signaling pathway into an 
attractive therapeutic target. VEGF blockers belong to two broad categories 
including: (I) VEGF ligand-blocking drugs and (II) drugs blocking VEGFR 
signaling. The use of neutralizing antibodies and other inhibitors has 
demonstrated that blockade of VEGF alone can substantially suppress tumor 
growth and angiogenesis in several experimental models. This has led to the 
development of the neutralizing anti-VEGF antibody bevacizumab, the first FDA-
approved antiangiogenic molecule (Quintieri et al, 2014). Bevacizumab is 
currently used in a variety of therapeutic protocols (some including 5-fluorouracil) 
for solid tumors, particularly those for tumors of gastrointestinal and pulmonary 
origin (see table 1.1). Besides blockade of VEGF, also multi-targeted tyrosine 
kinase inhibitors, such as sorafenib and sunitinib, which block several tyrosine 
kinase receptor-mediated pathways, including VEGFR, represent a novel 
approach to angio-suppression (Presta et al, 2009). 
 Not surprisingly, given the redundancy of factors involved in the regulation 
of the angiogenic process, also other angiogenic factors and signaling pathways -
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such as FGFs and angiopoietins- have been considered as potential therapeutic 
targets. In particular, FGFRs and associated ligands are a family of well-validated 
targets for therapeutic interventions in cancer diseases in relation to their 
prominent roles in cell growth, survival, differentiation and angiogenesis. 
Modulators of FGF or FGFR expression used to block completely or partially the 
activities of the FGF-FGFR complexes result in clinical drug candidates (Herbert 
et al, 2014). Overall, the current anti-angiogenic treatments when used alone 
have provided only a modest survival benefit (Mosele et al, 2014). Thus, there is 
increasing interest in combining antiangiogenic drugs with existing therapeutic 
modalities. As anti-angiogenics are generally cytostatic rather than cytoreductive, 
combinations involving conventional cytotoxic chemotherapies may be useful for 
maximizing therapeutic activity (Ma and Waxman, 2008).  
Preclinical studies have confirmed that angiogenesis plays a central role 
also in breast cancer and is associated with metastatic potential of breast 
tumors. The microvessel density of breast cancers is known to be predictive of 
micrometastases, tumor recurrence and overall survival, establishing 
angiogenesis as a potential therapeutic target for breast cancer (Mackey et al, 
2012). The anti-angiogenic drugs used in the setting of breast cancer comprise 
the monoclonal antibody bevacizumab, and multitargeted tyrosine kinase 
receptor antagonists such as sunitinib. Bevacizumab, for example, is highly 
recommended for triple negative phenotype (i.e. tumors not expressing estrogen, 
progesterone or Her2/neu receptor genes), which are highly proliferative tumors 
with high levels of VEGF Bevacizumab has been also approved for the use in 
metastatic breast cancer (Longatto et al, 2010; Miller et al, 2007).  
Although the recognized beneficial effects of anti-angiogenic drugs in 
different tumors (see table 1), the currently used anti-angiogenic therapies has 
been also associated with a number of adverse events, including vascular 
complications (Daher and Yeh, 2008). The mechanisms of such toxicity are 
thought to involve the induction of endothelial dysfunction due to inhibition of 
vascular relaxation and impairment of VEGF functions. In addition, it is important 
to underline that the clinical benefit of anti-angiogenic drugs is restricted because 
of intrinsic and acquired limitations: (I) decrease the delivery of cytotoxic drugs to 
tumors, and hence reduce their efficacy, (II) intrinsic resistance characterized by 
tumor indifference to anti-angiogenic therapy, and (III) increase tumor 
aggressiveness in some cancer types due to pro-invasive mechanisms and 
increased dissemination and metastasis (Mosele et al, 2014). 
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 Emerging concepts suggest that, in addition to growth factors, vascular 
metabolism also regulates angiogenesis and is a viable target for manipulating 
the microvasculature. It is well known that endothelial cells rely on glycolysis for 
ATP production, and recently has been shown that the key glycolytic protein 6-
phosphofructo-2-kinase/fructose-2,6-bisphosphatase 3 (PFKFB3) regulates 
angiogenesis. Thus, pharmacological blockade of PFKFB3 causes a transient, 
partial reduction in glycolysis, and reduces pathological angiogenesis with 
minimal systemic harm (Stapor et al, 2014). 
 This quest for angiogenesis inhibitors is not confined to conventional 
chemo-preventative compounds but extends to substances found in the diet, 
such as PUFAs, which have long been associated with lower rates of cancer 
(Spencer et al, 2009). 
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Drug Target Structure Indications 
Bevacizumab All VEGF isoforms mAb mCRC, mRCC, NSCLC, 
rGBM, metastatic breast 
cancer  (EMA approval), 
advanced ovarian cancer 
(EMA approval) 
Sunitinib VEGFR 1-3, c-Kit, PDGFR-
α and -ȕ, RET, CSF-1R, 
and FLT3 
TKI mRCC, GIST, PNET 
Sorafenib VEGFR 2-3, PDGFR-ȕ, 
FLT3, c-Kit, CRAF, BRAF, 
and P38-alpha 
TKI mRCC, advanced HCC 
Pazopanib VEGFR 1-3, c-Kit, PDGFR-
α and -ȕ, FGFR-1 and-3, c-
Kit, and c-Fms 
TKI mRCC, advanced ovarian 
cancer, soft tissue sarcoma 
Cediranib VEGFR 1-3 and c-kit TKI mCRC, recurrent ovarian 
cancer 
Aflibercept PIGF, VEGF-A, and VEGF-
B 
Fusion 
protein 
mCRC 
Regorafenib VEGFR 1-3, c-Kit, PDGFR-
α and -ȕ, FGFR 1-2, TIE2, 
RET, DDR2,RAF-1, and 
BRAF 
TKI mCRC, GIST 
Vandetanib EGFR, VEGFR, RET, TIE2, 
and Src 
TKI Advanced medullary thyroid 
cancer 
Trebananib 
[AMG 386] 
Ang-1/2 Peptibody Recurrent ovarian cancer 
Brivanib FGFR-1 and VEGFR-2 TKI Advanced HCC 
 
Table 1.1: Overview of anti-angiogenic drugs approved for clinical use in 
cancer (Quintieri et al, 2014). c-Fms: transmembrane glycoprotein receptor tyrosine 
kinase, c-kit: stem cell factor receptor, CSF-1R: colony stimulating factor-1 receptor, 
EGFR: epidermal growth factor receptor, FGFR: fibroblast growth factor receptor, FLT3: 
fetal liver tyrosine kinase receptor-3, GIST: gastro-intestinal stromal tumor, HCC: 
hepatocellular carcinoma, mCRC: metastatic colorectal cancer, mRCC: metastatic renal 
cell carcinoma, NSCLC: Non-small cell lung cancer, PDGFR: platelet derived growth 
factor receptor, PIGF: placental growth factor, PNET: Pancreatic Neuro-ectodermal 
tumor, RAF: murine leukemia viral oncogene homolog, RET: rearranged during 
transfection, rGBM: recurrent glioblastoma, Src: v-src sarcoma viral oncogene homolog, 
TIE2: tyrosine kinase with immunoglobulin like and epidermal growth factor like domains 
2, VEGF: vascular endothelial growth factor, VEGFR: vascular endothelial growth factor 
receptor, mAb: monoclonal antibody, TKI: small molecule tyrosine kinase inhibitor. 
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1.3. Fatty acids 
 In the body, fatty acids (FAs) deriving from the dietary fats or synthesized 
endogenously from acetyl CoA (Comba et al, 2011) are incorporated in blood 
lipids, fat deposits or structural lipids in biological membranes. Chemically, a FA 
is a carboxylic acid with an aliphatic tail. The predominant fatty acids are straight 
chain, can be saturated or contain carbon double bonds with an even number of 
carbon atoms and are termed ‘unsaturated fatty acids’. When the FA contains 
one double bond, it is called ‘monounsaturated’ (MUFAs; e.i. palmitoleic acid, 
16:1). If it contains more than one double bond, it is called ‘polyunsaturated’ 
(PUFAs, e.i. arachidonic acid, 20:4) (Ratnayake et al, 2009).  
 There are at least four families of PUFAs, depending on the parent FAs 
from which they are synthesized. The Ȧ-9 and the Ȧ-7 series are synthesized in 
our body starting from oleic acid (OA, 18:1 Ȧ-9) and palmitoleic acid (PA, 16:1 Ȧ-
7), respectively (Calder, 2013). In addition, there are 18-carbon PUFAs, Ȧ-3 and 
Ȧ-6 series of PUFAs derived from α-linolenic acid (ALA 18:3, Ȧ-3) and linoleic 
acid (LA, 18:2 Ȧ-6), respectively. Since humans cannot synthesize ALA and LA, 
they are considered essential fatty acids (EFAs) (Azrad et al, 2013). LA and ALA 
are synthesized in large quantities in plants, while they are not produced in 
humans and other mammals because of lack of Δ12- desaturase and Δ15- 
desaturase, the enzyme that allow synthesize of EFAs. Although animals cannot 
synthesize ALA or LA they can metabolize them by further desaturation and 
elongation (Calder, 2013). EFAs metabolism is shown in Figure 1.3. 
 Among the main dietary sources of LA are vegetable oils such as 
sunflower, safflower and corn oil (Das, 2011), while chia and rapeseed oils are 
rich in ALA (Espada et al, 2007; Das, 2011). LA is the predominant PUFA in the 
Western diet, and it is converted to arachidonic acid (AA, 20:4 Ȧ-6), while ALA is 
converted via desaturases and elongases to yield the eicosapentaenoic acid 
(EPA, β0:5 Ȧ-3), which can be further elongated to docosahexaenoic acid (DHA, 
ββ:6 Ȧ-3) (Azrad et al, 2013). 
 Plant (ALA) and marine (EPA and DHA) Ȧ-3 FAs used to be abundant in 
traditional Mediterranean diets. These Ȧ-3 PUFAs are considered as the major 
mediators of the protective effect provided by this diet. On the other hand, 
Western diet is rich in Ȧ-6 compared to Ȧ-3 FAs and this PUFA profile has been 
associated with higher breast cancer risk (Das, 2011; de Lorgeril and Salen, 
2012).  
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1.3.1. Essential Fatty Acids  
 Starting from ALA and LA which are considered respectively, Ȧ-γ and Ȧ-6 
essential fatty acids (EFAs) incorporated through the diet different PUFAs are 
synthesized (Figure 1.3). The term omega (Ȧ or n) is a structural descriptor for a 
family of PUFAs. “Ȧ” signifies the position of the double bond that is closest to 
the methyl terminus of the acyl chain of the fatty acid. For example, all Ȧ-3 fatty 
acids have this double bond on carbon 3, counting the methyl carbon as carbon 
one (Calder, 2013). The structure of Ȧ-γ and Ȧ-6 EFAs is shown in Figure 1.4. 
 As mentioned above, mammalian cells metabolize EFAs by successive 
elongation and desaturation reactions. Enzymes endowed with elongase and 
desaturase activities, such as Δ5- and Δ6, metabolize different PUFAs families. 
In eukaryotic cells, these enzymes are localized on the cytosolic face of the 
endoplasmic reticulum (Grammatikos et al, 1994). As shown in Figure 1.3, ALA 
can be converted to stearidonic acid (SDA, 18:4 Ȧ-3), which can be further 
elongated to eicosatetraenoic acid (ETA, 20:4 Ȧ-3) by Δ-6 desaturase. ETA is 
then desaturated by Δ-5 desaturase to yield EPA. It is important to note that the 
conversion of ALA to EPA (Ȧ-3 family) is in competition with the conversion of LA 
to AA (Ȧ-6 family), since the same enzymes are used (Figure 1.3). In particular, 
PUFA precursors compete with each other for the same enzymes, with 
hierarchical preference given for Ȧ-γ over Ȧ-6 FA (Das, 2011).  
 Several factors are known to influence the metabolism of EFAs. For 
example, saturated fats, cholesterol, trans-fatty acids, alcohol, adrenaline, and 
glucocorticoids inhibit Δ6 and Δ5-desaturases. Pyridoxine, zinc, nicotinic acid, 
and magnesium are co-factors for normal Δ6-desaturase activity. Moreover, the 
activities of Δ5 and Δ6-desaturases are slow in humans (Δ5>Δ6). As a result, the 
conversion of LA and ALA to their respective metabolites may be inadequate 
under certain circumstances. In such an instance, it is necessary to supplement 
EPA and ϊHA (to bypass Δ5 and Δ6-desaturases). Generally, supplementation 
of AA is not necessary since; it can be obtained from the diet (Das, 2011). 
 Following dietary intake, Ȧ-3 PUFAs are incorporated into cell 
membranes in all tissues of the body (Surette, 2008) where they play important 
roles in membrane structure, potentially influencing membrane functions and 
transmembrane and intracellular protein activity via a number of mechanisms 
(Lundbæk et al, 2010). Feeding laboratory animals a diet containing fish oil, 
which provides EPA and DHA, results in a higher content of these fatty acids in 
the cell membrane of lymphocytes, macrophages, Kupffer cells and neutrophils; 
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typically, an enrichment in marine Ȧ-3 PUFAs is accompanied by a decrease in 
AA content (Calder, 2013). Several studies showed that Ȧ-3 PUFAs incorporation 
differs between individuals due to dissimilar rates of metabolism, enzymatic 
activity, background diet, age, and sex (Arterburn et al, 2006). For example, DHA 
and EPA plasma concentrations measured from day 7 to day 28 were 
significantly higher than at baseline in healthy subjects receiving a 28-day oral 
treatment with 3 g/day of DHA/EPA (Rusca et al, 2009). Moreover, plasma EPA 
concentrations increase in a linear manner in response to dietary EPA, whereas 
dietary DHA causes a dose-dependent, saturable increase in plasma 
phospholipid DHA concentrations with doses up to 2 g/day. Both DHA and EPA 
similarly reduce AA concentrations in plasma. Overall, tissue content of long-
chain Ȧ-3 fatty acids increases in response to dietary DHA or EPA 
supplementation (Arterburn et al, 2006). 
Once incorporated into cell membranes, esterified PUFAs are released by 
the action of several different phospholipase A2 (PLA2s) (Calder 2013). In 
particular, it has been demonstrated that DHA release from astrocytes is provided 
by Ca2+-independent PLA2 (iPLA2), whereas AA is mainly released by another 
isoform, the Ca2+-dependent PLA2 (cPLA2) (Strokin et al, 2004). In the case of 
endothelial cells, bovine aortic endothelial cells (BAECs) incorporate EPA as well 
as DHA when these fatty acid are present in the culture medium (Hadjiagapiou et 
al, 1986; Hadjiagapiou and Spector, 1987). PUFAs either released from cell 
membranes or from dietary intake are substrate for cyclooxygenases (COXs), 
lipoxygenases (LOXs) and cytochrome P450 (CYP450), three families of 
enzymes that generate bioactive lipid mediators (Shimizu et al, 2009).  
 AA acting as a substrate for COX enzymes leads to prostaglandins and 
thromboxanes (Samuelsson et al, 1978). In addition, complex families of 
prostaglandin isomers called isoprostanes derive as free radical products of 
oxidative metabolism (Hamberg et al, 1975). LOX enzymes metabolize AA to 
leukotrienes and lipoxins, and CYP450 enzymes to hydroxyeicosatetraenoic and 
epoxyeicosatrienoic acids. These lipid mediators play critical roles in diverse 
physiological and pathological processes, such as cancer (Greene et al, 2011). 
 Besides AA, also Ȧ-3 PUFAs can be metabolized by COXs, LOXs and 
CYP450. A widely accepted theory explain that the health-promoting effects of Ȧ-
3 PUFAs is that they suppress the metabolism of AA or serve as alternative 
substrates to generate Ȧ-3 lipid mediators with beneficial actions (Rose and 
Connolly, 1999). In particular, it is believed that the protective effects of EPA 
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(β0:5 Ȧ-3) are based upon a) preventing conversion of AA to pro-inflammatory 
eicosanoids (prostaglandins and leukotrienes),  b) serving as an alternate 
substrate producing 5-series leukotriens that are less potent; and/or c) 
conversion by cyclooxygenase (COX) to 3-series prostanoids (such as PGI3). 
These explanations have not been generally accepted because of the lack of 
molecular evidence in vivo and the high concentrations of Ȧ-3 PUFAs required to 
achieve putative beneficial actions in vitro (Serhan et al 2000). Other potential 
mechanisms associated to the protective role of PUFAs will be discussed in more 
details later (see on page 38).  
 
 
Figure 1.3: Conversion of essential ω‐6 and ω‐3 PUFAs to their longer 
chain, more unsaturated derivatives (Siddiqui et al, 2008). 
 
 
 
 
Figure 1.4: Structural representation of 18-carbon fatty acids. 
PUFAs with 2 and 3 double bonds. a) LA (18:β Ȧ-6) and b) ALA (18:γ Ȧ-3). The 
red numbers represents the carbon atoms counting from the methyl end of the 
chain (Ȧ).  
b) 
a) 
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1.3.2. The Role of PUFAs in tumorigenesis  
 Fatty acids may promote or inhibit cancer. In the current literature there 
are inconsistent data about the potential role or implication of PUFAs in 
carcinogenesis. Several studies have found that, MUFAs and Ȧ-6 PUFAs 
promote tumor growth, while Ȧ-3 PUFAs may exert inhibitory action (Vara-
Messler et al, 2015; Azrad et al, 2013). 
 Ȧ-3 PUFAs, mainly EPA and DHA, have been shown to have multiple 
antitumor actions that affect all of the alterations that dictate malignant growth 
(Stephenson et al, 2011) reported above (see on page 35). We will report some 
examples of this large body of evidence from laboratory-based studies that 
support a beneficial effect of Ȧ‐3 PUFAs on the hallmarks of cancer (Stephenson 
et al, 2011). 
Ȧ-3 PUFAs profoundly affect growth factor signal transduction, with 
numerous putative pathways identified in the in vitro and in vivo setting. For 
example, it has been demonstrated that EPA and DHA have beneficial effects on 
breast cancer cells growth through a marked decrease of epidermal growth factor 
receptor (EGFR) expression in lipid rafts, leading to alteration in EGFR signaling 
(Schley et al, 2007). Indeed, it has been shown that Ȧ-3 PUFA exerts anti-cancer 
effects by reducing the expression of some growth factors including human 
epidermal growth factor receptor-2 (HER-2), epidermal growth factor receptor 
(EGFR) and insulin-like growth factor receptor 1 (IGF-1R), inhibiting cell 
proliferation by either activating PPARȖ or decreasing levels of fatty acid 
synthase (FAS) protein and/or promoting cell apoptosis via blocking PI3K/Akt 
pathways, downregulating phosphorylated Akt and lowering Bcl-2/Bax ratio (Liu 
et al, 2004). In addition, in vivo studies demonstrated that the levels of COX-2 
and its metabolite PGE2 are reduced by supplementation of Ȧ-3 PUFAs. In 
particular, it has been shown that reduced levels of COX-2 and PGE2 were 
related to a reduction in tumor growth in a prostate cancer cell xenograft in mice 
(Rao et al, 2001). Moreover, in a rodent model of breast cancer, DHA induced a 
reduction in mammary tumor accompanied by an upregulation of BRCA 1 (breast 
cancer 1) tumor suppressor protein, thus suggesting that Ȧ‐3 PUFAs affect tumor 
sensitivity to growth-inhibitory signals (Jourdan et al, 2007). In vitro, EPA derived 
metabolites of COX and LOX have been shown to decrease growth of human 
breast cancer cell lines (Rose and Connolly, 1990), while in xenografted rats 
carrying a neuroblastoma tumor supplementation with a DHA-enriched diet prior 
to tumor cell injection delayed tumor formation. In the same study, it was 
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investigated the effect of DHA as a therapeutic agent in rats who had established 
tumors. Tumors in animals receiving high dose DHA showed response better 
response in terms of disease progression compared to animals receiving low 
dose DHA or controls (Gleissman et al, 2011). Another study performed in a 
pancreatic tumor xenograft in nude mice showed tumor inhibition by DHA 
(Swamy et al, 2008).  
Ȧ-3 PUFAs affect also tumor evasion of programmed cell death, which is 
a complex process controlled by an intricate milieu of intra-cellular signal 
transduction pathways. Evidence suggests that DHA and EPA have beneficial 
effects on many of these pathways. For example, an increased induction of 
apoptosis with Ȧ-3 PUFAs has been demonstrated on HT-29 colon cell line 
(Chen and Istfan, 2000; Clarke et al, 2000). Other studies have shown that DHA 
induces a dose-dependent effect on cancer cell apoptosis (Gleissman et al, 
2011; Lindskog et al, 2006). EPA and DHA have also been shown to modulate 
the expression of the Bcl-2 family proteins. In particular, they downregulate anti-
apoptotic proteins Bcl-2 and Bcl-xL and increase the levels of the pro-apoptotic 
proteins Bak and Bcl-xS (Gleissman et al, 2010). In a mouse model of colon 
carcinogenesis the initiation of tumor growth was restricted by increased 
apoptosis related to Ȧ-3 PUFAs supplementation (Hong et al, 2000). 
There are also evidence for effects of Ȧ-3 PUFAs on tumor invasion and 
metastasis, which may be decreased by EPA and DHA supplementation. EPA 
and DHA have been demonstrated to affect tumor cell migration through the 
suppression of tumor derived nitric oxide (NO) production (Ohata et al, 1997). 
Inhibition of metastasis by Ȧ-3 PUFAs enriched diets has been demonstrated in 
both mouse and rat models of colorectal cancer (Iwamoto et al, 1998; 
Kontogiannea et al, 2000). EPA and DHA have also been shown to suppress 
development of lung metastases (Rose and Connolly, 1996). 
In addition, Ȧ-3 PUFAs have also been shown to have a profound effect 
on angiogenesis. Experiments in which breast carcinomas were implanted into 
nude mice fed with diets high in EPA or DHA indicated that both tumor 
microvessel density counts and levels of VEGF measured in the resected tumors 
were significantly lower in animals receiving these Ȧ-3 PUFAs (Rose and 
Connolly, 1999). Consistently, Ȧ-3 PUFAs inhibits primary mammary tumor 
growth through modulation of selected determinants of vascularization in a 
murine model of breast cancer (Mukutmoni-Norris et al, 2000). Besides PUFAs, 
also lipid mediators from Ȧ-3 PUFAs may play a role in angiogenesis. This issue 
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will be discussed further (see on page 48). Overall, the in vitro studies on 
different cell culture models as well as in vivo studies in animals widely suggest 
that Ȧ-3 PUFAs have promising anticancer effects. Conversely, the data in 
humans are controversial. In respect to epidemiological evidence, several 
prospective cohort studies investigated the association between PUFAs (either 
specific fatty acids or mixtures) and risk for cancer (Azrad et al, 2013). In 
particular, on the epidemiological studies on breast cancer produced inconsistent 
findings. In the Multiethnic Cohort Study, no association between PUFAs and risk 
for breast cancer was observed. In contrast, the Vitamins and Lifestyle (VITAL) 
study showed a trend toward a protective association for both EPA and DHA 
dietary intake and breast cancer risk. Additionally, when EPA and DHA from diet 
and also supplementation with fish oil were considered, both EPA and DHA were 
significantly associated with reduced risk for breast cancer. Besides, in the 
French E3N study population the intake of Ȧ-3 PUFAs per se showed no 
association with breast cancer risk, except in subjects also consuming higher 
amounts of Ȧ-6 PUFAs. Finally, in the Shanghai Women’s Health Study, no 
association between PUFAs and breast cancer risk was found. Taken together, 
the studies indicated that the ratio of Ȧ-3 to Ȧ-6 rather than Ȧ-3 per se is 
important to reduce breast cancer risk. The discrepancy observed between 
studies may reflect the difficulties in collecting accurate dietary data; however, it 
also may reflect genetic variation in PUFAs metabolism which has been shown to 
modify physiological levels of PUFAs and cancer risk (Witte and Hardman, 2015).  
An interventional study in breast cancer patients where DHA was 
combined with FEC 75 chemotherapy [intravenous infusion of cyclophosphamide 
(500 mg m−2) and fluorouracil (500 mg m−2), followed by epirubicin (75 mg m−2) 
showed delayed time to tumor progression and longer overall survival with 
respect to FEC alone. However, these findings were only observed when patients 
were stratified into 2 groups of either high or low incorporation of DHA into 
plasma and erythrocytes. Patients who had higher incorporation of DHA into 
plasma and erythrocytes benefited compared to those who had lower DHA 
incorporation (Bougnoux et al, 2009).  
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1.4. Cyclooxigenases and their metabolites 
Cyclooxygenases (COXs), also known as prostaglandin endoperoxide 
synthase (PGHS), are the enzymes responsible for the conversion of AA or other 
fatty acids into the various prostanoids, a family of lipid mediators that have 
widespread and diverse biological function. AA represents the main substrate for 
COXs which are the enzymes responsible for the transformation of AA in the 
unstable intermediate known as prostaglandin H2 (PGH2). PGH2 can be further 
metabolized into the 2-series prostanoids by tissue specific isomerases such as 
prostacyclin synthase (PGI2s) and prostaglandin E2 synthase (PGE2s) to originate 
prostacyclin (PGI2) and prostaglandin E2 (PGE2), respectively (Smyth et al, 2009). 
Also, EPA has been deeply investigated for its metabolism by COXs since 
it is an analogue of AA. Through the COX pathway, EPA is converted into 
prostaglandin H3 (PGH3) and after that to PGs and TXs of the 3-series. These 
prostanoids exert a number of specific functions, sometimes opposite to those 
exerted by the 2-series prostanoids (Lagarde et al, 2013). Besides AA and EPA, 
also DHA is highly susceptible to oxidation by COXs. For example, COX-2 
converts DHA to 13-hydroxy-DHA (13-HDHA) in human microvascular 
endothelial cells (Christie, 2011). It is widely accepted that DHA-derived 
metabolites switch the classical AA derived pro-inflammatory toward anti-
inflammatory mediators. In addition, DHA when metabolized by LOX can act as a 
precursor of metabolites promoting tissue repair (Figure 1.5) (Serhan et al, 2002). 
More recently, it has been demonstrated that aspirin-acetylated COX-2, in 
the presence of AA as a substrate endogenously produces a number of novel 
lipid mediators called AT-Lipoxins, which exerts protective effects both in vitro 
and in vivo. In the presence of substrates different from AA such as DHA and 
EPA, aspirin-acetylated COX originates other metabolites endowed with anti-
inflammatory activity (Figure 1.5) (Serhan et al, 2002). Overall these metabolites 
including lipoxins (from AA), E-resolvins (from EPA) and D-resolvins (from DHA), 
are called aspirin-triggered metabolites (Figure 1.5). The combined use of DHA 
and aspirin became an attractive therapeutic avenue for the treatment of 
inflammatory related conditions (Makriyannis and Nikas, 2011). We will further 
discuss specific roles of these metabolites (see on page 51). COXs exist in two 
main isoforms: COX-1 constitutively expressed under basal conditions in most 
cells including vascular endothelial cells, and COX-2 which is primarily an 
inducible enzyme, but it is now known to be constitutively expressed in specific 
cells including endothelial cells. COX-2 has been mainly associated with a variety 
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of clinical inflammatory states and increased cell replication or differentiation; for 
instance COX-2 is upregulated by growth factors, tumor promoters, as well as by 
cytokines (Smyth et al, 2009).  
 
1.4.1. COX-2 in the setting of tumors  
In respect to the role of COXs in cancer development, COX-1 expression 
remains unaltered in most of cancers, although some findings indicate that COX-
1 might play a role in intestinal polyposis and ovarian cancer. COX-1 might also 
be responsible for prostanoids synthesis at early stages in pre-cancerous lesions 
(Salvado et al, 2012). In contrast, COX-2 is overexpressed in a series of human 
cancers such as lung, breast, stomach, prostate, ovarian, head and neck, 
pancreatic, brain, gliomas, melanomas and colorectal adenocarcinomas. While 
there are several data on the involvement of COX-2 in tumor, the molecular 
mechanisms through which COX-2 contributes to tumorigenesis have not been 
yet completely identified (Rizzo et al, 2011). In particular, it has been 
demonstrated that COX-2 contributes to neovascularization, which is essential for 
tumor progression. Among the various prostanoids, PGE2 is the best studied in 
the context of tumor progression. Both endothelial and tumor cells produce PGE2. 
The production of prostanoids in the vasculature is due to the presence of both, 
COX-1 and COX-2 isoforms. COX-2 is inducible in cultured endothelial cells and 
human vessels following stimulation by pro-inflammatory factors, including IL-1ȕ, 
TNF-α which are also abundant in the tumor microenvironment (Gately, 2000). 
Co-culturing endothelial and tumor cells has been reported to promote COX-2-
dependent endothelial cells motility and assembly into capillary-like structures, an 
effect attributed to the release of angiogenic peptides, nitric oxide, and 
prostaglandins such as PGE2 from the tumor cells. An alternative interpretation is 
that prostanoids synthesized by endothelial COX-2 might contribute to this effect, 
and recent findings support the idea that COX-2 expression in the tumor 
endothelium might promote tumor growth and neovascularization by producing 
bioactive prostanoids with paracrine actions on nearby cancer cells. This 
suggests that the landscaping tumor promoter action of endothelial COX-2 would 
arise both from its ability to synthesize prostanoids intracellularly and via 
transcellular metabolism through crosstalk with neighboring tumor cells. Indeed, 
transcellular metabolism could be a common mechanism for producing PGE2 
with crosstalk occurring between endothelial, stromal, tumor, and other cells 
present in the tumor microenvironment (Salvado et al, 2009; Salvado et al, 2012).  
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In particular, in human breast cancer the role of COX-2 as a critical 
component of tumor progression has been thoroughly investigated. COX-2 is 
upregulated in 40% of breast cancers, with up to 84% increases in some studies. 
Moreover, COX-2 plays a crucial role as a prognostic factor for malignancy and 
has been associated with carcinogenesis, particularly neoangiogenesis and 
tumor progression. As for the role of COXs in breast cancer related angiogenesis, 
it was demonstrated that COX-2 induces the expression of angiogenic factors, 
such as VEGF, basic fibroblast growth factor (bFGF), transforming growth factor 
1 (TGF-1), platelet-derived growth factor (PDGF) and endothelin. In particular 
COX-2 derived PGE2 binds at its receptor thus enhancing VEGF expression 
(Hoellen et al, 2011).  
 
1.4.2. Pro-resolving aspirin-triggered metabolites 
Aspirin, the first chemically produced medication was synthesized in the 
1850s and continues to be widely used for its analgesic and anti-inflammatory 
properties. However, aspirin has also served as an invaluable pharmacological 
probe for unraveling several aspects of the inflammatory syndrome. During the 
1970s, John Vane demonstrated that aspirin attenuates the biosynthesis of 
prostaglandins by acting as an inhibitor of COX-1. This discovery served as a 
basis for the development of a number of the widely used non-steroidal anti-
inflammatory drugs (NSAIDs) (Makriyannis and Nikas, 2011). To date, aspirin is 
well appreciated for its ability to irreversibly inhibit COX-1 and inactivate this 
enzyme, blocking both PGs and TXs production in cells that possess these 
biosynthetic pathways. The mechanism of aspirin’s action involves acetylation of 
COX within the enzyme’s catalytic region. This prevents alignment of the 
substrate AA for oxygenation within the catalytic center that produces the 
prostaglandin endoperoxide intermediate (PGG2).  
Aspirin’s action within cells that possess COX-2 is different. The catalytic 
region of COX-2 is larger than that of COX-1, and when it is acetylated by aspirin, 
the biosynthesis of endoperoxide is blocked. Yet, unlike COX-1, acetylated COX-
2 remains active producing a number of metabolites in the presence of different 
substrates. In particular, aspirin-acetylated COX-2 generates 15R-HETE (15-
hydroxy-eicosatetraenoic acid) from AA, 18R-HEPE (18-hydroxy-
eicosapentaenoic acid) from EPA and 17R-HDHA (17-hydroxy-docosahexaenoic 
acid) from DHA (Figure 1.5). The first aspirin-acetylated COX-2 metabolite 
characterized was derived from AA, and was termed 15R-HETE. 15R-HETE, 
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18R-HEPE and 17R-HDHA can be further transformed by 5-LOXs expressed in 
human neutrophils and macrophages to aspirin-triggered lipoxins (AT-L) or 
aspirin-triggered resolvins (AT-Rvs). This process of cell-cell cooperation is 
termed transcellular metabolism or transcellular biosynthesis, and could 
represent an important contribution to the profile of lipid mediator produced in 
physiological as well as in pathologic circumstances by a particular organ or cell. 
The resulting metabolites have potent anti-inflammatory effects inhibiting human 
neutrophil migration and enhancing macrophage clean up overall improving the 
resolution of inflammation (Serhan et al, 2011).  
Endothelial cells are able to incorporate different PUFAs into cell 
membrane phospholipids and to convert them into specific metabolites. In bovine 
aortic endothelial cells, it has been demonstrated that EPA as well as DHA are 
incorporated in the cell membrane phospholipids. Moreover, when DHA or EPA 
were available, less AA was incorporated into membrane phospholipids, and in 
turn converted to prostacyclin (PGI2) (Hadjiagapiou and Spector, 1987). 
Conversely, in BAECs chronically supplemented with EPA or DHA PGI3 
production increased indicating that when challenged with EPA or DHA 
endothelial cells easily convert EPA to PGI3 (Hishinuma et al, 1999). When 
treated with aspirin, EPA enriched human vein endothelial cells (HUVECs) or 
microvascular cells generate 18R-HEPE, that is released and further converted to 
AT-RvE1 by activated human neutrophils through 5-LOX (Serhan et al, 2000). On 
the other hand, in presence of DHA, aspirin-treated endothelial cells generate 
17R-HDHA, which can be further metabolized by 5-LOX to AT-RvD1 (Serhan et 
al, 2002).  
Specialized pro-resolving mediators (SPM) including those derived from 
COX-2 such as AT-Rvs have been shown to directly promote the resolution of 
inflammation (Serhan et al, 2011). The majority of the evidence comes from 
animal models. For example, the role of aspirin-triggered resolvin D1 (AT-RvD1) in 
immune complex-induced lung injury has been determined in mice. Lung 
vascular permeability was significantly reduced in the AT-RvD1-treated mice 
when compared to control mice. Furthermore, administration of AT-RvD1 caused 
a significant decrease in the broncho-alveolar lavage fluid content of neutrophils, 
inflammatory cytokines, and chemokines. Of interest, it has been demonstrated 
that IgG immune complex-induced activation of NFκB was significantly inhibited 
by AT-RvD1 (Tang et al, 2014). Additionally, intra venous (iv) administration of 
AT-RvD1 1h after LPS challenge protected mice from kidney injury associated 
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with tubular damage by decreasing neutrophil infiltration and by suppressing 
LPS-induced ICAM-1 and VCAM-1 expression in the kidney (Chen et al, 2014). 
The in vivo protective effects of this family of compounds have been 
demonstrated also in other disease models. RvE1 treatment significantly 
increased post-traumatic sleep in brain-injured mice while AT-RvD1 treatment 
mitigated motor and cognitive deficits suggesting that AT-RvD1 may impart 
functional benefit through mechanisms other than resolution of inflammation 
alone (Harrison et al, 2015). Moreover, in a model of endometriosis in female 
Sprague-Dawley rats both RvD1 and AT-RvD1 significantly decreased vascular 
permeability in ectopic endometrial tissue and AT-RvD1 alleviated the severity of 
vaginal hyperalgesia, suggesting that these compounds can be considered for 
further investigation of their therapeutic potential in endometriosis (Dmitrieva et 
al, 2014). Finally, in the setting of pathological angiogenesis, AT-Lipoxin (a 
downstream metabolite of COX-2 acetylated in presence of AA) (Figure 1.5) as 
well as RvE1 and RvD1 reduce inflammatory corneal angiogenesis (Jin et al, 
2009).  
AT-L leads to the resolution of inflammation, for example, AT-L blocks the 
generation of reactive oxygen species in endothelial cells, and it is a potent anti-
inflammatory, inhibiting cell chemotaxis of polymorphonuclear (PMN) cells, 
leukocyte-endothelial interaction and NFkB activation as well as tumor necrosis 
factor-alpha (TNF-α) secretion in activated T cells. Accordingly, AT-L shows 
promise for treating a number of inflammatory diseases, as it possesses potent 
protective actions in a variety of experimental animal models of disease, including 
peritonitis, colitis, dermal inflammation, ischemia-reperfusion injury, and 
periodontitis. Also, AT-L reduces the PMN-endothelial cell adhesion initiated by 
preeclamptic plasma when human PMN were incubated with AT-L prior to 
addition to endothelial monolayers (Romano et al, 2015). Besides AT-metabolites 
from AA, also AT-EPA metabolites were characterized. In vitro, HUVECs treated 
with ASA convert EPA to 18R-HEPE. In vivo, 18R-HEPE blocked PMN infiltration 
and trans-endothelial migration and inflammation in a murine air pouch (Serhan 
et al, 2000). In addition, the biological activity of 18R-HEPE was examined using 
a murine model of zymosan-induced peritonitis. 18R-HEPE (2.5 μg) or vehicle 
alone was administered intraperitoneally at the time of zymosan-A injection. 18R-
HEPE significantly reduced neutrophil infiltration as compared to vehicle alone 
(Krishnamurthy et al, 2011). Consistently, AT-RvE3 (a downstream metabolite of 
18R- or S- HEPE) has been proved to be a potent inhibitor of PMN chemotaxis in 
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vitro and also significantly reduced PMN numbers in zymosan-induced peritonitis 
model in vivo. Intravenous administration of 18R- and 18S-RvE3 (10 ng/mouse) 
gave 30-45% inhibition of PMN infiltration that was maintained at the 100ng 
doses (Isorbe et al, 2012).  
Recently, healthy volunteers were supplemented with Ȧ-3 PUFAs (2.4 
g/day) for 7 days with random assignment to take aspirin (300 mg/day) or 
placebo. Blood was collected at baseline and after 7 days. Plasma 18R/S-HEPE 
and 17R/S-HDHA as well as derivated E and D series resolvins were measured. 
Supplementation with Ȧ-3 PUFAs significantly increased RvE1, 18R/S-HEPE and 
17R/S-HDHA, thus demonstrating that these metabolites are formed in vivo in 
humans. However, the addition of aspirin after Ȧ-3 PUFAs supplementation did 
not affect AT-metabolite generation (Barden et al, 2014). Also, the study of Oh et 
al showed that in blood samples from volunteers receiving aspirin (81 mg at 12 
and 24h) prior to a single dose (1 g) of fish oil the concentrations of the 18R-
HEPE isomer in human plasma were 3-folds higher than the 18(S)-HEPE (Oh et 
al, 2011).  
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Figure 1.5: Outline of the pathways of PUFAs metabolism (Vara-Messler et 
al, 2015). LA (linoleic acid); ALA (α- linoleic acid); AA (arachidonic acid); DGLA (dihomo-
gamma-linolenic acid); EPA (eicosapentaenoic acid) or DHA (docosahexaenoic acid); 
ASA (aspirin); COX (cyclooxygenase); LOX (lipoxygenase); CYTP450 (cytochrome 
P450); HODE (hydroxyoctadecadienoate); HOTE (hydroxyoctadecatrienoate); PGs 
(prostaglandin); TXs (thromboxane); LTs (leukotriene); HETEs (hydroxyeicosatetraenoic 
acid); HEPE (hydroxy-eicosapentaenoate); EETs (epoxyeicosatrienoic acid); EDPs 
(epoxydocosapentaenoic acid); HDHA (hydroxy-docosahexaenoic acid); AT (aspirin-
triggered). 
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In this thesis, we will focus on the role of metabolites generated in DHA-
treated cells from aspirin acetylated COX-2, namely 17R-HDHA, an upstream 
metabolite of AT-RvsD, which is generated by endothelial cells (Figure 1.5). Until 
now, the role of 17R-HDHA and the downstream metabolites were extensively 
characterized in vitro and in vivo models by Serhan (Serhan et al, 2002). In 
particular, these metabolites have been studied in the setting of inflammation. For 
instance, di- and tri-hydroxy products derived from 17R-HDHA inhibited microglial 
cell cytokine expression in an in vivo model of dermal inflammation and peritonitis 
by reducing 40-80% leukocytic exudates (Serhan et al, 2002). In addition, it has 
been demonstrated that a systemic treatment with 17R-HDHA (as well as its 
downstream metabolites, AT-RvD1, RvD2) in a nanogram range greatly improved 
disease activity index, body weight loss, colonic damage, and polymorphonuclear 
infiltration in two models of experimental colitis. Also, these treatments reduced 
colonic cytokine levels, as well as mRNA expression of NFkB and adhesion 
molecules (Bento et al, 2011). Additionally, decreased colitis activity was 
demonstrated in another murine model. The analysis of lipid mediators showed a 
sustained formation of DHA-derived 17R-HDHA after treatment with ASA and 
DHA. Overall, the results showed a protective effect of ASA and DHA in a murine 
colitis model and could give a rationale for a careful reassessment of ASA 
therapy in patients with inflammatory bowel disease and particularly ulcerative 
colitis, possibly combined with DHA supplementation (Köhnke et al, 2013). The 
effects of 17R-HDHA have been also evaluated in adjuvant-induced arthritis in 
rats treated with mechanical and thermal stimuli. Under these experimental 
conditions, 17R-HDHA, given systemically, inhibited the development and the 
maintenance of mechanical hyperalgesia (Lima-Garcia et al, 2011).  
Of interest, at the end of ’90, the Gruppo Italiano per lo Studio della 
Sopravvivenza nell’Infarto Miocardico (GISSI-Prevenzione) reported data on the 
protective effect of Ȧ-3 PUFAs in aspirin treated patients. Patients (n=11323) 
surviving a very recent myocardial infarction (MI) were randomized to 1.0 g daily 
of fish oil Ȧ-3 PUFAs (PUFAs, n=2835), vitamin E (300 mg daily, n=2830), both 
(n=2830), or no treatment (n=2828) (GISSI, 1999). This study provided evidence 
that Ȧ-3 PUFAs supplementation decrease cardiovascular death of about 45%. 
However, the impact of ASA alone was not evaluated (Serhan et al, 2002).  
Overall, these results indicate that at sites of inflammation-resolution Ȧ-3 
PUFAs in the presence of aspirin generate novel oxygenated bioactive products. 
Given their potent actions, the production of AT-metabolites may, in part, provide 
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a molecular rationale underlying the beneficial actions of Ȧ-3 PUFAs in 
neoplasia, chronic immune and cardiovascular diseases and serve for new 
therapeutic development.  
 
1.5. Role of PUFA-derived metabolites in angiogenesis 
Angiogenesis, one of the necessary steps in tumor growth and 
metastasis, is influenced by Ȧ-6 and Ȧ-3 PUFAs, as well as their downstream 
metabolites produced by either COX, LOX or CYT P450 (Figure 1.5). It is 
generally believed that Ȧ-6 PUFAs and their metabolites promote tumor 
angiogenesis through a variety of signaling pathways, encouraging cell 
proliferation and migration, and decreasing tumor apoptosis. Conversely, Ȧ-3 
PUFAs and their metabolites are endowed with anti-angiogenic properties. Given 
that Ȧ-6 and Ȧ-3 PUFAs have opposing effects and compete for the same 
enzymes, lowering ratio Ȧ-6:Ȧγ PUFA ratio shows great potential for controlling 
pathological angiogenesis and reducing cancer development (Kang and Liu, 
2013). 
 
1.5.1. Arachidonic acid metabolites and angiogenesis  
The pro-angiogenic effects of COX-2 are mediated primarily by products 
of AA metabolism such as prostaglandin E2 (PGE2) and thromboxane A2 (TXA2). 
A number of tumor overexpressed COX-2 and COX-2 derived PGE2 induces 
tumor-associated angiogenesis through an increased expression of VEGF. 
Indeed, in a preclinical breast cancer model, COX-2 inhibition by celecoxib 
suppresses angiogenesis and tumor growth, prevents metastases, and increases 
overall survival (Xin et al, 2012). COX-2 has been found overexpressed also in 
pulmonary, colonic, and mammary tumors as compared to negligible levels of 
COX-2 in non-neoplastic epithelium. Furthermore, patients with metastases have 
higher COX-2 expression, PGE2 levels, and microvessel densities than cancer 
patients without metastases (Kang et al, 2013). Under hypoxic conditions, COX-
2/PGE2 enhances HIF-1 transcriptional activity, which in turn increases VEGF 
levels, angiogenesis and tumor cell survival in this hostile environment 
(Greenhough et al, 2009). Besides, it has been shown that PGE2-mediated 
elevation of intracellular cAMP level leads to an increase in eNOS activation and 
endothelial NO and cGMP production by PKA-dependent PI3K/Akt activation and 
then promotes angiogenesis in vitro and ex vivo (Namkoong et al, 2005). 
Recently, it has been established a role also for COX-1 in angiogenesis. Indeed, 
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it has been demonstrated that the PGE2 biosynthesis was dependent on COX-1, 
rather than COX-2 since neither the pharmacological inhibition nor COX-2 gene 
silencing affected PGE2 production and angiogenesis evaluated by the formation 
of capillary like structures in vitro (Salvado et al, 2013). Moreover, it was 
demonstrated that other COX metabolites including PGJ2 and its derivative PGD2 
dose-dependently inhibit tube formation in endothelial cells in vitro while PGE1 
(from ϊGLA, β0:γ Ȧ-6) and PGE2, had no significant effects. Indeed, 15d-PGJ2 
was the most potent inhibitor of HUVEC tube formation (Xin et al, 1999; Mousa et 
al, 2013). In line with these results, Kim et al. (2006) demonstrated that in 
endothelial cells treated with 15 deoxy-PGJ2 VEGFR-1 and 2 mRNA levels were 
reduced and this in turn was associated with its anti-angiogenetic activity (Kim et 
al, 2006).  
In addition, others COX metabolites have been demonstrated to have a 
role in angiogenesis. The inhibition of endogenous TXA2 biosynthesis with a 
thromboxane synthase inhibitor, CI (20 µM) reduced VEGF or bFGF stimulated 
endothelial cell migration in vitro and bFGF-induced angiogenesis in vivo (Nie et 
al, 2000). Consistently, the TXA2 receptor (TP) agonist U46619 stimulated while 
a TXA2 receptor antagonist, inhibited endothelial cell migration in response to 
VEGF or bFGF. In the context of cardiovascular disease where revascularization 
and angiogenesis play a protective role, it has been reported that HUVECs 
express both TPα and TPȕ. The signaling downstream TPȕ but not TPα 
stimulation abrogates the pro-angiogenic and chemotactic properties of VEGF on 
endothelial cells and that the mechanism of inhibition involves the suppression of 
NO and FAK/Src activation. Overall these data suggest a different role for the 2 
TP receptor subtypes in mediating angiogenesis: Stimulation of TPα receptors 
produced no inhibition of VEGF-induced angiogenesis, while TPȕ expression is 
necessary and sufficient to reduce the angiogenic potential of VEGF-treated ECs 
in the presence of TP ligands (Ashton et al, 2004).  
Beside COX metabolites, also metabolites derived from LOX have been 
described to modulate the angiogenic process. In particular, metabolites derived 
from 5-LOX have been demonstrated to increase angiogenesis. Indeed, 5-LOX 
inhibitors decreased the incidence of colonic adenoma formation and this was 
associated to reduced angiogenesis, decreased activity of the metalloprotease 2 
(MMP-2) as well as decreased VEGF protein expression in the colons of tumor 
bearing animals (Ye et al, 2004). In line with this result, in a rat mammary tumor 
model, the overexpression of 5-LOX has been accompanied by the increase in 5-
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HETE and LTB4 production as well as the increase of key angiogenic factors 
such as MMP-2 and VEGF (Chatterjee et al, 2013). Beside 5-LOX, also 12-LOX 
through its metabolite 12(S)-HETE has been demonstrated to have a pronounced 
pro-angiogenic effect. Prostate tumors bearing mice overexpressing 12-LOX 
showed a remarkable increased angiogenesis with respect to healthy mice 
evidenced by a high microvascular density. Moreover, 12(S)-HETE has been 
shown to stimulate endothelial cell migration and to up-regulate the surface 
expression of integrin αvȕ3 (an integrin predominantly associated with angiogenic 
blood vessels) in tumors. The potential of 12(S)-HETE as a significant stimulator 
of pathological angiogenesis may lie in its ability to induce the VEGF gene and 
protein expression (Pidgeon et al, 2007). In regards to 15-LOX metabolites, there 
are conflicting results and both pro- and anti-angiogenic effects have been 
demonstrated. In particular, lipoxin A4 pretreatment of endothelial cells has been 
shown to be associated with anti-angiogenetic effects against various pro-
angiogenesis stimulus such as bFGF or VEGF (Mousa et al, 2013), while 15(S)-
HETE have been demonstrated to have pro-angiogenetic effect (Soumya et al, 
2012).  
It is well recognized that arachidonic acid can be metabolized also by CYT 
P450 epoxygenases giving rise to epoxygenated fatty acids (EpFAs) such as 
epoxyeicosatrienoic acids (EETs) (Spector et al, 2015). These lipid mediators are 
known to regulate various biological processes including angiogenesis. The pro-
angiogenic effect of EETs was firstly demonstrated in astrocytes co-cultured with 
endothelial cells where EETs released from astrocytes stimulated endothelial cell 
proliferation and tube formation. Further in vitro studies showed that treatment 
with synthetic EETs stimulated angiogenesis in endothelial cells. In particular, 
11,12- and 14,15-EETs have been shown to increase endothelial cell 
proliferation, migration and invasion. Animal studies were followed up to support 
the pro-angiogenic effects of EETs. Consistently, treatment with 11,12- or 14,15-
EET stimulated neovascularization in a Matrigel plug assay and a chicken 
chorioallantoic membrane assay. Moreover, 5,6- and 8,9-EET stimulated 
angiogenesis in a subcutaneous sponge assay in mice (Zhang et al, 2014). 
Additionally, it has also been demonstrated that EETs elicit endothelial cell 
proliferation and angiogenesis increasing COX-2 gene and protein expression 
(Michaelis and Fleming, 2006) or up regulating VEGF-A expression (Panigrahy et 
al, 2011). Overall, evidence largely supports a pro-angiogenic role for AA and its 
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metabolites. The exception is represented by the PGD2 metabolite 15 deoxy-
PGJ2. 
To summarize, two lines of evidence support the pro-angiogenic effects of 
AA metabolites; first, high eicosanoid concentration due to high activity of COX-2, 
12-LOX, 5-LOX and CYP 450 upregulate pro-angiogenetic factors through a 
variety of mechanisms. Second, inhibition of COX-2, 12-LOX and 5-LOX 
attenuates angiogenesis through downregulating pro-angiogenetic factor (Kang 
and Liu, 2013).  
 
1.5.2. EPA and DHA metabolites and angiogenesis  
Ȧ-3 PUFAs can exert their anti-angiogenic properties mainly by two main 
mechanisms: 1) by inhibiting the production of pro-angiogenic metabolites 
derived from AA or 2) by producing anti-angiogenic metabolites from COXs, 
LOXs or  cytochrome P450 (CYP) enzymes. 
As we previously explained, Ȧ-3 PUFAs work as “natural inhibitors” of Ȧ-6 
eicosanoids. Moreover, Ȧ-3 PUFAs inhibited the production of many important 
angiogenic mediators such as VEGF, PDGF, COX-2, PGE2, nitric oxide, and 
matrix metalloproteinases (Spencer et al, 2009).  
For example, in vitro exposure of endothelial cells to DHA under 
conditions that efficiently incorporate DHA into membrane phospholipids 
decreased stimulated COX-2 mRNA transcription and COX-2 protein expression 
as well as the production of AA-derived metabolites with a role in angiogenesis 
(Massaro et al, 2007; Pola et al, 2004). Moreover, it has been demonstrated that 
Ȧ-3 PUFAs are able to inhibit VEGF expression in colon cancer cells involving 
the negative regulation of the COX-2/PGE2 pathway (Dommels et al, 2003). 
Several in vitro and in vivo studies on animal models show that Ȧ-3 PUFAs have 
inhibitory effects on COX-2 and PGE2 production by tumor cells (Spencer et al, 
2009). 
Besides suppressing the formation of pro-angiogenic eicosanoids from AA 
(β0:4, Ȧ-6) by endothelial and cancer cells (Spencer et al, 2009; Salvado et al, 
2009; Salvado et al, 2012), Ȧ-3 PUFAs are capable to biosynthesize specific 
anti-angiogenetic lipid mediators. In particular, the roles of COXs metabolites in 
the presence of Ȧ-3 PUFAs have been studied in vitro. It has been demonstrated 
that PGE3, that is biosynthesized from EPA by COX metabolism, did not 
stimulate the pro-angiogenic mediator angiopoietin-2 (Ang-2) differently from AA-
derived PGE2 (Szymczak et al, 2008). These findings are consistent with the 
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suggestion that PUFAs undergo biotransformation by COX-2 to generate lipid 
mediators that modulate tumor angiogenesis. Regarding the specific role of EPA 
in angiogenesis, it has also been demonstrated that human umbilical vein 
endothelial cells (HUVECs) treated with EPA decreased VEGF-stimulated tube 
formation and angiogenesis. In addition, VEGF-stimulated migration of HUVECs 
was suppressed and certain matrix metalloproteinases (MMPs) associated with 
endothelial cell migration was diminished in HUVECs treated with EPA (Tsuzuki 
et al, 2007). Moreover, a study on the effect of EPA on VEGF-induced endothelial 
cell proliferation showed that bovine carotid artery endothelial cells treated with 
EPA displayed a dose-dependent suppression of VEGF-induced endothelial cell 
proliferation (Yang et al, 1998). In vivo, rats with fibrosarcoma were assigned to 
diets supplemented with corn oil, normal saline or EPA. After resection of the 
tumor, rats on EPA diet had significantly decreased levels of VEGF-α mRNA, 
demonstrating that EPA supplementation inhibits tumor growth, potentially 
through alterations in the expression of the pro-angiogenic VEGF-α (Tevar et al, 
2002). Few data are available on the role of DHA metabolites on angiogenesis. 
Recently, a key role for 4-HDHA (a metabolite from DHA by 5-LOX metabolism) 
has been described. 4-HDHA has potent effects in inhibiting endothelial cell 
sprouting (Sapieha et al, 2011). Moreover, it has been demonstrated in vivo that 
increasing Ȧ-3 PUFAs tissue levels by dietary or genetic modification decreased 
the avascular area of the retina by increasing vessel regrowth after injury, thereby 
reducing the hypoxic stimulus for neovascularization. More interesting, the 
bioactive Ȧ-3 PUFAs derived mediators NPD1, RvD1 and RvE1 also potently 
protected against neovascularization (Connor et al, 2007). Besides the role on 
COXs- and LOXs-derived metabolites, Ȧ-3 PUFAs are also substrates of 
cytochrome P450 (CYP) epoxygenases. This enzyme, for example, synthetizes 
epoxydocosapentaenoic acids (EDPs) from DHA. It has been recently reported 
that EDPs suppressed endothelial cell migration and protease production via a 
VEGF receptor 2-dependent mechanism. Also, EDPs inhibited VEGF- and FGF 
2-induced angiogenesis in vivo. Moreover, when EDPs are co-administered with 
a low-dose soluble epoxide hydrolase inhibitor, EDPs are stabilized in circulation, 
causing ∼70% inhibition of primary tumor growth and Overall, EDPs mediates the 
angiogenic switch to decrease tumor growth (Zhang et al, 2013). Thus, Ȧ-3 
PUFAs, through COX, LOX or cytochrome P450 (CYP) enzymes are able to 
synthetize metabolites which are able to directly affect angiogenesis as well as to 
counteracting the pro-angiogenic actions of Ȧ-6 PUFAs (Kang and Liu, 2013).  
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1.5.3. Aspirin-triggered metabolites and angiogenesis 
Aspirin-acetylated COX-2 metabolite from AA (20:4, Ȧ-6) are named 
aspirin-triggered lipoxins (AT-L), while those from EPA (20:5, Ȧ-3) or from DHA 
(22:6, Ȧ-3) are named aspirin-triggered resolvins (AT-Rvs) from E or D series, 
respectively. The impact of AT-L and their analogues on angiogenic pathways, 
such as endothelial proliferation, VEGF and VEGF receptor expression has been 
well characterized (Romano et al, 2015), while few data are available on AT-Rvs. 
It has been reported that 15-epi-16-(parafluoro)-phenoxy-lipoxin A4 (AT-L1), the 
stable analogue of AT-L, inhibits angiogenesis by inhibiting VEGF-stimulated 
endothelial migration in a concentration-dependent manner. Moreover, AT-L1 
inhibited endothelial cell proliferation in cells stimulated with VEGF. In vivo, in a 
granuloma model of inflammatory angiogenesis, AT-L1 treatment (10 g/mouse) 
reduced by approximately 50%  angiogenic parameters (Fierro et al, 2002). 
Moreover, ATL-1 inhibited EC adhesion to fibronectin via interaction with its 
specific receptor. Furthermore, VEGF-induced MMP-9 activity and expression 
were reduced by pretreatment with AT-L1. AT-L1 inhibited NFκB nuclear 
translocation and strongly decreased VEGF-dependent phosphorylation of 
phosphainositide 3-kinase (PI3-K) as well as extracellular signal-regulated 
kinase-2 (ERK-2), two signaling kinases involved in EC proliferation (Cezar-de-
Mello 2008). Furthermore, AT-L1 modulates essential components of the motile 
process, by impairing actin polymerization and focal adhesion assembly. 
Pretreatment of EC with AT-L1 caused a reduction in VEGF-induced stress fibers 
and therefore reduced the intracellular content of filamentous actin. A 
concomitant impairment in stress-activated protein kinase (SAPK2/p38) 
phosphorylation suggests that ATL-1 inhibition of VEGF-stimulated actin 
polymerization involves the SAPK2/p38 pathway. Moreover, ATL-1 treatment 
inhibited focal adhesion clustering due to inhibition of focal adhesion kinase 
(FAK) phosphorylation and the subsequent association of FAK with the actin 
cytoskeleton. Together these results provide evidence that AT-L1 inhibits EC 
migration via the concerted inhibition of actin polymerization and proper assembly 
of focal adhesions, supporting a role for these novel lipid mediators as 
angiogenesis modulators (Cezar-de-Mello 2006). To date, few studies have 
addressed the role of resolvins series E and D, derived from the metabolism of 
EPA and DHA, respectively. It has been demonstrated that besides AT-L, RvE1 
and RvD1, reduced inflammatory corneal hematoangiogenesis. Mice treated with 
these lipid mediators have had reduced mRNA expression of VEGF (A, C and 
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R2), TNF-α, IL-1 alpha, IL-1 beta, and suppressed hemoangiogenesis, but not 
lymphangiogenesis. In addition, AT-L directly inhibits VEGFA-mediated corneal 
neovascularization and is the most potent inhibitor of angiogenesis among these 
lipid mediators (Jin et al, 2009).  
 
At our knowledge, there is no data on aspirin-acetylated COX-2 derived 
DHA metabolites in the setting of tumor-angiogenesis.  
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2. AIM OF THE STUDY  
 
The general objective of the present study was to determine the role of 
dietary Ȧ-3 polyunsaturated fatty acids (PUFAs) from chia oil on a syngeneic 
mouse model of breast cancer (BC). The major specific aim of this thesis work 
was to investigate the effects of docosahexaenoic acid (DHA 22:6, Ȧ-3) 
metabolites from aspirin-acetylated COX-2 in angiogenesis. The present work 
began in Argentina, where mice were fed a chia oil-rich diet containing α-linolenic 
acid (ALA 18:3, Ȧ-3). Ex vivo and in vitro angiogenesis experiments have been 
carried out in Italy. 
Cancer is the leading cause of mortality worldwide, and the tumor with the 
largest number of incident and prevalent cases is BC. Beside the highest 
prevalence and incidence, BC is also the most frequently occurring tumor in 
women (Ferlay et al, 2014). Angiogenesis is a tightly regulated process that 
contributes to tumor growth, which is controlled by a balance of pro- and anti-
angiogenic molecules. The angiogenic process represents an important target to 
suppress tumor growth and metastasis; however, patients become resistant to 
anti-angiogenic therapy over time. Moreover, currently used drugs have been 
associated with several side effects including bleeding and defects in wound 
healing (Moserle et al, 2014).  
Epidemiological and preclinical data have linked Ȧ-3 PUFAs consumption 
to a lower incidence of BC. Furthermore, experiments performed in breast 
carcinoma-implanted mice fed diets rich in Ȧ-3 PUFAs showed that tumor 
microvessel density in resected tumors were significantly lower with respect to 
control diet-fed animals. Consistently, a fish oil-based diet rich in Ȧ-3 PUFA, 
inhibits primary mammary tumor growth through modulation of vascularization in 
this murine model of BC (Mukutmoni-Norris et al, 2000). Moreover, it has been 
shown that dietary intake of ALA from flaxseed suppresses breast tumor growth 
in ovariectomized athymic BALB/c mice (Chen et al, 2007). Previously published 
data from the Argentinian lab demonstrated that ALA-rich diets based on mystol 
or perilla oils reduced mammary tumor growth (Muñoz et al, 1995; Nakamaya et 
al, 1993). In addition, preliminary data demonstrated that the ALA-rich oil from 
chia (Salvia hispanica L.) seeds, used by pre-Hispanic civilization living in South 
America, significantly reduces growth of a transplantable mammary 
adenocarinoma in mice. At present, the role of an ALA-enriched diet in tumor 
angiogenesis has not been addressed. Conversely, several in vitro and in vivo 
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studies have shown that docosahexaenoic acid (DHA 22:6, Ȧ-3), a downstream 
metabolite from ALA, as well as DHA epoxymetabolites, decrease angiogenesis, 
while arachidonic acid (AA 20:4, Ȧ-6) promotes angiogenesis (Kang and Liu, 
2013; Zhang et al, 2013). Several COX-1 and COX-2 AA-derived eicosanoids 
have shown to have a pro-angiogenic effect (Salvado et al, 2013; Nie et al, 2000; 
Pola et al, 2004). In particular, AA-derived PGE2 has been largely studied in the 
context of tumor progression, including the angiogenic process.  
In addition, whereas COX-1 acetylated by aspirin (ASA) is permanently 
inactivated, acetylated COX-2 is still capable to metabolize PUFAs to a novel 
series of specialized lipid mediators with pro-resolving activity. In particular, 
acetylated COX-2 in presence of either AA or Ȧ-3 PUFAs generates several 
metabolites including 18R-HEPE from eicosapentaenoic acid (EPA 20:5, Ȧ-3) 
and 17R-HDHA from DHA (Serhan, 2014). Interestingly, metabolites produced in 
vivo by Ȧ-3 PUFAs have potent anti-inflammatory effects and considering that 
inflammation can stimulate angiogenesis, it is possible to hypothesize that 
reduced inflammation modulates angiogenesis in vivo. However, although the 
ability of metabolites from ASA-acetylated COX-2 to promote the resolution of 
inflammation is well recognized, their direct role in angiogenesis is almost 
unexplored (Connor et al, 2007).  
 
The present study was aimed at evaluating the role of metabolites 
generated by ASA-acetylated COX-2 in the presence of either DHA or AA in 
several in vitro models of angiogenesis. The study of metabolites required for 
antiangiogenic and, more generally, anti-tumor effects of Ȧ-3 PUFA is relevant 
considering the high degree of inter-individual variability in metabolizing fatty 
acids. This may explain, at least in part, the inconsistent results from clinical trials 
of Ȧ -3 PUFAs in human cancer (Wang et al, 2014). 
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3. MATERIALS AND METHODS 
 
3.1. Materials 
 
Ȧ-3 PUFAs source, chia seed oil, was purchased from Nutraceutica Sturla 
S.R.L. (Argentina), while Ȧ-6 PUFAs source, corn seed oil was purchased from 
Arcor S.A. (Argentina). LM3 cells, a line of murine mammary cancer cells, were 
kindly provided by Dr. Bal de Kier-Joffe (Instituto Oncologico Angel Roffo, 
Argentina). Fatty acids, as well as 17R-HDHA were obtained from Cayman 
Chemical (Ann Arbor, MI, USA) and fatty acids-methyl esters standard came from 
Nu-Chek Prep Inc (Minneapolis, MN, USA).  
MIB-5 mAb  (for Ki-67), as well as secondary Ab HRP labelled anti-rabbit 
and 3,3'-diaminobenzidine (DAB) was purchased from DAKO Corp (Carpinteria, 
CA, USA). The Fluorometric kit TUNEL System was purchased from Roche 
Applied Sciences (Mannhein, Germany) and VEGF Receptor 2 mAb from Cell 
Signaling Technology, Inc. (Danvers, MA, USA). CD31 anti-human Ab was 
purchased from BD Biosciencies Pharmingen (San Diego, CA, USA). 
Matrigel® was purchased from Becton Dickinson (Waltham, MA, USA) 
and DiffQuick staining kit from Thermo Fisher Scientific Inc (Waltham, MA, USA). 
Hematoxylin and eosin, trypsin 0.25%-EDTA, Minimal Essential Medium (MEM) 
and Medium 199 (M199), fetal bovine serum (FBS), endothelial cell growth factor 
(ECGF), antibiotics solution (10.000 U/mL penicillin/10 mg/mL streptomycin), as 
well as other analytic grade chemical agents were purchased from Sigma-Aldrich 
(St. Louis, MO, USA).  
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3.2. Study design for in vivo and in vitro studies 
 
Figure 3.1: A schematic line drawing the experimental approach. 
 
3.3. In vivo experiments  
 
3.3.1. Mice and diets 
After weaning, 40 BALB/c mice (male and female) were randomized and 
housed in polycarbonate cages in groups of four. Animals were kept in a 12h light 
and 12h darkness cycle at a constant temperature of 23°C. Animal studies were 
conducted in accordance with the Guidelines set by the National Institutes of 
Health (NIH) - Guide for the Care and Use of Laboratory Animals. All the 
procedures were approved by the Institutional Committee for the Care and Use of 
Laboratory Animals at the Facultad de Ciencias Médicas (Universidad Nacional 
de Cordoba, Argentina). Animals were fed with two isocaloric diets (3.86 Kcal/g) 
differing in their fatty acid composition. The final composition of both diets 
consisted of (%): casein (16.0), sucrose (34.0), corn starch (39.0), fiber (2.0), salt 
mixture (3.5) and vitamin mixture (0.5). The chia oil diet (ChO) contained chia oil 
(10.0) and the control diet contained corn oil (CO) (10.0). Food and water were 
provided ad libitum. As previously published (Espada et al, 2007), the fatty acid 
composition of chia oil used for dietary oil supplementation showed 
approximately a 60% ALA (18:γ, Ȧ-γ) and β0% LA (18:β, Ȧ-6), whereas corn oil 
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contains around 50% of LA and trace amounts of ALA (Table 3.1). Values for the 
oils agree with those published by the American Oil Chemists Society (Adlof, 
2003). Animals were inspected daily; food consumption and weight were 
recorded weekly. 
 
 
 Table 3.1: Fatty acid composition (%) of corn and chia oil added to the diet. 
 Values represent mean of each fatty acid. Common names: 14:0 Myristic acid, 16:0 
Palmitic acid, 18:0 Stearic acid, 18:2 Linoleic acid, 18:3 α-Linolenic acid. PUFAs: 
polyunsaturated fatty acids; MUFA: monounsaturated fatty acids; FA: fatty acids. 
 
3.3.2. Tumor induction and cancer cell culture 
LM3 cells were isolated from mouse mammary gland tumors that 
exhibited moderate metastatic behaviour (Bal de Kier Joffre et al, 1983). LM3 
cells were maintained in MEM, supplemented with 10% (v/v) fetal bovine serum, 
1% antibiotics solution (10000 U/mL penicillin/10 mg/mL streptomycin) and 
incubated at 37°C under 5% CO2. Mice have been fed for three months with 
either the ChO or the CO diet, and after that tumor was induced with LM3 murine 
cancer cell line (106 cells in β00 μl fresh MEM) injected subcutaneously into the 
left flanks of the mice. in order to obtain a syngeneic breast cancer murine model. 
After tumor induction mice were fed with their respective diets. Meanwhile, the 
latency time (days) for palpable tumors was recorded. Animals were sacrificed at 
45 days after inoculation.  
 
3.4. Ex vivo experiments 
 
3.4.1. Tumor parameters 
During necropsy, tumor weight (g), volume (mm3) and the number of 
grossly macroscopic metastasis were recorded in all organs of the host fed 
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animals with the aid of magnifying lens, as published in previous studies (Espada 
et al, 2007). Samples from tumor tissues were fixed in 4% (w/v) 
paraformaldehyde and, after that tissues were dehydrated and embedded in 
paraffin for histological analyzes. Histological analyses were performed on 
sections from 3 animals for each dietary condition. 
 
3.4.2. Apoptosis and mitosis determination 
Apoptotic and mitotic figures were recognized by characteristic 
morphological changes in fixed tumor tissues stained with hematoxylin and eosin 
(HE). Apoptotic figures were recognized by shrinking, condensing and 
fragmenting of nuclei, and mitotic figures as cells on metaphases (Figure 3.2).  
 
 
Figure 3.2: Apoptotic and mitotic figures from tumors.  
Apoptotic (a) and mitotic (b) figures from neoplastic tumor tissue fixed in 4% 
paraformaldehyde, dehydrated, embedded in paraffin and stained with hematoxylin and 
eosin (100x magnification). 
 
Terminal deoxynucleotidyl transferase (TdT) dUTP Nick-End Labeling 
(TUNEL) assay has been used to detect apoptotic cells that undergo extensive 
DNA degradation during the late stages of apoptosis (Kyrylkova et al, 2012). An 
in situ cell death detection kit Fluorometric TUNEL System assay was conducted 
in the paraffin-embedded tumors. Tumor sections were dewaxed and rehydrated. 
After that, slides were immersed in 0.85% (w/v) NaCl for 5 minutes and samples 
were permeabilizated with 0.25% (v/v) Triton X-100 in PBS buffer (TBS). Tumor 
sections were labeled adding 50 μl of TdT reaction mix and slides were incubated 
for 1h at 37°C in a humidified chamber avoiding exposure to light. The reaction 
was stopped by washing for 15 minutes and slides were counterstained with 4',6-
diamino-2-fenilindol (DAPI) to visualize all nuclei.  
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Ki-67 staining was performed in order to detect mitotic cells. Ki-67 nuclear 
antigen is expressed in cell cycle S, G1, G2, and M phases, but is non-existing in 
G0 phase (Inwald et al, β01γ). Tumor sections (8 μm thickness) were dewaxed 
and rehydrated. Following, antigen retrieval was performed bringing the slides to 
boil in 1mM Na-citrate buffer pH: 6.0 during 45 minutes at 95ºC. Sections were 
washed and endogenous peroxidase activity was blocked with 3% hydrogen 
peroxide for 15 minutes. Non-specific binding sites were blocked with 3% albumin 
in Tris-buffered saline buffer, 0.1% Tween-20 (TBST) for 1h. The staining with 
MIB-5 mAb (1:400) was performed overnight at 4ºC. After incubation, slides were 
washed three times and sections were covered with a secondary Ab (HRP 
labelled polymer) for 1h. After that, sections were developed with 3,3'-
diaminobenzidine (DAB) for 10 minutes at room temperature and counterstained 
with hematoxylin. 
 
TUNEL and Ki-67 positive cells in ten high-power fields were counted in a 
blinded manner from three animals for each dietary condition using a light 
microscope equipped with a digital camera (40x magnification) Olympus BH2. 
Results were expressed as a mean ± SEM of TUNEL or Ki-67 positive cells/mm2. 
 
3.4.3. Angiogenesis determination 
It has been shown that downregulation of VEGF-Receptor 2 (VEGFR-2) 
resulted in a significant reduction of the sprouting capability and hence in 
decreasing angiogenesis. Angiogenesis was determined by 
immunohistochemistry (IHω) in embedded paraffin tumor sections (4 μm 
thickness). Sections were dewaxed, rehydrated and antigen retrieval was 
performed bringing the slides to boil in 1 mM ethylenediaminetetraacetic acid 
(EDTA) pH: 8.0 during 15 minutes at 95ºC. After that, sections were washed and 
endogenous peroxidase activity was blocked with 3% hydrogen peroxide for 10 
minutes. Non-specific binding sites were blocked with 5% serum in Tris-buffered 
saline buffer 0.1% Tween-20 (TBST) for 1h. The staining with VEGF-R2 Rabbit 
mAb (1:250) was performed overnight at 4ºC. After incubation, slides were 
washed three times in TBST and sections were covered with a secondary Ab 
(HRP labelled polymer anti-rabbit) for 1h. Subsequently, sections were developed 
with 3,3'-diaminobenzidine (DAB) for 10 minutes at room temperature and 
counterstained with hematoxylin. Vessels were counted in ten high-power fields 
in a blinded manner from three animals for each dietary condition using a Nikon 
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Eclipse Ti equipped with a digital camera (40x magnification). Results were 
expressed as a mean ± SEM of vessel density/mm2. 
 
3.5. In vitro experiments 
 
3.5.1. Endothelial cell isolation and culture 
Human umbilical vein-endothelial cells (HUVECs) were obtained from 
human umbilical cords. Cords were washed with 0.9% (w/v) NaCl and enzyme 
digestion [0.1% (w/v) collagenase] was performed at 37°C for 15 minutes. 
HUVECs were eluted with a phosphate saline buffered and collected by 
centrifugation at 1100 rpm for 5 minutes. Pelleted HUVECs were suspended in 
fresh M199 supplemented with 15% (v/v) FBS, 1% (v/v) gentamicin, 0.1 mg/mL 
(w/v) endothelial cell growth factor (ECGF), and 100 g/mL (w/v) heparin and 
placed in T-25 flask kept in a humidified atmosphere of 95% air and 5% CO2 at 
37°C. To determine the culture purity, HUVECs (5 x 104 cells) were incubated 
with an anti-CD31 antibody or with an isotype control IgG1 antibody at room 
temperature. An unstained sample was included and cells were analysed by flow-
cytometry. The background staining observed in isotype controls was subtracted 
from the signals obtained in CD31+ cells. Flow cytometry analysis of CD31 
revealed that purity of isolated HUVECs was 99.6% (corrected by background 
subtraction) (Figure 3.3). We have randomly performed a similar experiment in 
order to control cell purity. 
 
 
Figure 3.3: Representative image of CD31-positive cells.  
Percentage of endothelial cells defined by CD31-positive cells. 
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3.5.2. Endothelial cell treatments 
HUVECs were used at 2nd to 6th passage. Cells were treated from 24 to 
72h with DHA (1-50 μM) or AA (1-50 μM) in the presence or absence of ASA (50 
µM). Selected experiments were performed with 17R-HDHA (100 nM - 3 µM), a 
DHA metabolite derived from COX-2 acetylated by ASA.  
 
3.5.3. MTT assay for cell viability determination  
The MTT reduction assay was performed to determine cell viability. The 
yellow 3-(4,5- dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) salt is 
converted to purple formazan crystals by the succinatetetrazolium reductase 
system of the mitochondrial respiratory chain, which is active in viable cells only. 
HUVECs (at the density of 2 x 103, 1.5 x 103 or 104 cells/well) were seeded in 
96-well plates in 100 µl medium/well. Cells were incubated overnight to allow 
adhesion. Cells were treated for 24 to 72h with different concentrations of DHA 
(1-50 μM) or AA (1-50 μM) in the presence or absence of ASA (50 µM) and 17R-
HDHA (100 nM - γ µM); four hours before the end of protocol, 10 μl of MTT [5 
mg/mL (w/v)] was added to each well. Finally, the incubation medium was 
removed and the formazan crystals were dissolved in 100 μl/well dimethyl 
sulfoxide (DMSO). MTT reduction was quantified by measuring the light 
absorbance at 570 nm−6γ0 nm using a multilabel plate counter (VICTOR–
Wallac) (Stratford et al, 1989). Background absorbance from control wells (cell-
free media) was subtracted and the cell viability was expressed as a percentage 
of the control. 
 
3.5.4. Wound healing assay  
In order to determine haptotaxis, wound healing assay were conducted. 
HUVECs were seeded in a 12 well plate at the density of 105, 1.5 x 105 or 2 x 
105 cells/well depending on the duration of the experiment.  After 24h of 
adhesion cells were treated with DHA (1-50 μM) or AA (1-50 μM) in the presence 
or absence of ASA (50 µM) and  17R-HDHA (100 nM-3 µM) for 24 to 72h. After 
that, the cell monolayer was scraped using a sterile p1000-pipet tip and the 
debris were removed carefully by washing (Liang et al, 2007). The treatment was 
replaced and pictures were taken at time 0h (T0) and after 16h (T16) using a 
phase contrast inverted microscope Nikon Eclipse Ti equipped with a digital 
camera (4x magnification, 3 unit fields/well).  
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Quantitative analysis of cell migration was performed using an average 
wound space from those fields and the percentage of change in the wound space 
was calculated using the following formula:  
 
% change = (average space at T0) - (average space at T16) 
(average space at T0)*100. 
 
Relative cell migration was calculated by dividing the percentage change 
in the wound space of treated cells by that of the control cells in each experiment. 
Results were expressed as a percentage of cell migration. 
  
3.5.5. Boyden chamber assay  
Chemotaxis describes cell migration based on chemicals in a cell's 
surrounding environment. In order to evaluate the chemo-attractive effect of 17R-
HDHA, a chemotaxis assay was performed using a modified 48-well Boyden 
chamber with a polycarbonate 8-μm pore size membrane previously coated 
collagen [10mg/mL (w/v)].. HUVEC suspension (1.6 x 105 cells/mL) was seeded 
into the upper chamber to migrate toward a chemoattractant in the lower 
chamber (Boyden, 1962). In the lower chamber was placed either a medium 
supplemented with 15% (v/v) FBS (positive-control), a medium without FBS 
(negative-control) or a medium supplemented with 17R-HDHA (300 nM -γ μM). 
Following 6h incubation, HUVECs in the upper side of the membrane were 
removed and the membrane was immediately transferred to a dish with metanol 
and placed for 10 minutes at -20ºC in order to fix migrated cells. Thereafter, the 
membrane was stained with Diff-Quick® kit according to the manufacturer’s 
instructions. Pictures were taken with a microscope Nikon Eclipse Ti (20x 
magnification, 5 unit fields/well). Cells were counted using a Cell Counter 
plugging developed by Image-J (http://imagej.nih.gov/ij/ U.S. National Institutes of 
Health. Bethesda, Maryland, USA). Results were expressed as a percentage of 
migrated cells respect to the positive-control.  
 
3.5.6. Matrigel assay 
To assess the capability of endothelial cells to form capillary-like 
structures, HUVECs were seeded on Matrigel®, a soluble basement membrane 
extract of the Engelbreth-Holm-Swarm tumor that gels at room temperature to 
form a reconstituted basement membrane. HUVECs (2 x 104 cells/well) were 
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plated onto a thin layer of the basement membrane Matrigel® in a 48-well plate 
and incubated for 30 minutes at 37°C in a 5% CO2 for 6h in complete cell culture 
medium with or without tested compounds in presence of ECGF [100 mg/mL 
(w/v)]. At the end of protocol, the capillary-structures were observed using a 
phase contrast inverted microscope Nikon Eclipse Ti equipped with a digital 
camera and pictures were taken (40x magnification, 3 unit fields/well). Images 
were analysed using Angiogenesis Analyzer, a plugging developed by Image-J 
software (http://imagej.nih.gov/ij/ U.S. National Institutes of Health. Bethesda, 
Maryland, USA). Data on dimensional parameters (total tubule length) and 
topological parameters (number of nodes, junctions and meshes and total mesh 
area) of the capillary-like network were analysed in control and treated wells 
(Gandin et al, 2015). Results were expressed as a percentage of change from 
control cells. 
  
3.5.7. Liquid chromatography-tandem mass spectrometry analysis 
In order to verify the endogenous production of 17R-HDHA by HUVECs 
release, HUVEC supernatants from cells treated with DHA or ASA or DHA+ASA 
were harvested and were analysed by Liquid chromatography-tandem mass 
spectrometry. Samples were centrifuged to remove any cellular material. 50 μl of 
internal standard was added to 700 μl of sample. The resulting supernatants 
were immediately applied to C18 SPE cartridges that had been preconditioned 
with 1 mL Methanol and 1 mL water. Finally, the hydroxyl fatty acids were eluted 
using 400 μl of a solution composed by acetonitrile:methanol (65%:γ5%). 
Samples were evaporated to dryness with a speed vacuum and recovered in 100 
μl of a solution 70% (v/v) phase A (water, acetic acid 0.05%, pH: 5.7) and 30% 
(v/v) phase B (65% Acetonitrile and γ5% methanol). 10 μl of each samples were 
injected in a liquid chromatography Agilent 1100 equipped with a reverse phase 
column (Kinetex 5u C18, 50 x 2.1 mm). The column was eluted with a linear 
gradient from 30 to 100% solvent B (methanol:acetonitrile, 65:35) over 9 minutes 
(Solvent A: 0.05% acetic acid pH: 5.7 with ammonia). The effluent from the high-
performance liquid chromatography (HPLC) column was directly infused into an 
API4000 triple quadrupole operated in negative ion mode. Quantitation was 
performed using standard curves obtained with synthetic standard and recovery 
was calculated using deuterated internal standards. 
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3.6. Data analysis 
Data are expressed as means ± standard error (SEM) of at least three 
independent experiments. Statistical analysis was performed using t-Test (2-
tailed probability value) to compare two groups. Multiple comparisons were made 
by ANOVA followed by Dunnet multiple comparison tests using GraphPad Prism 
version 6.00 for Windows (San Diego, CA, US). Each of the p≤0.05 changes was 
considered statistically significant. 
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4. RESULTS 
 
4.1. ALA-enriched diet inhibits BC growth and metastasis 
40 BALB/c mice were fed for 90 days an α-linolenic (ALA)-rich diet (10% 
chia oil, ChO) or with a linoleic acid (LA)-rich diet (10% corn oil, CO) before tumor 
induction. At the end of the experimental protocol, 45 days after tumor induction, 
animals’ general status was optimal. Diet and water consumption were similar for 
both groups. Tumor incidence, considered as the number of mice which 
developed tumors at sacrifice, was higher in CO-fed mice (100%) compared with 
ChO-fed mice (ChO) (85%). Moreover, tumor weight (1.0 ± 0.2 vs 2.2 ± 0.2 g, 
p<0.05) and volume (4.4 ± 0.4 vs 7.2 ± 1.0 mm3, p<0.05) were lower in ChO- vs 
CO-fed mice, whereas the latency time (22 ± 1 vs 15 ± 2 d, p<0.05) was longer in 
ChO-fed mice. Likewise, ChO-fed mice had significantly fewer metastases when 
compared to CO-fed mice group (70 ± 0.8 vs 10 ± 0.1, p<0.05) (Figure 4.1). In 
particular, the highest percentage of metastases was located in the lung, 
retroperitoneum and liver. 
 
a)
CORN
CHIA
b)
Tumor Parameters CORN 
DIET
CHIA 
DIET
Tumor incidence (n) 20 17 *
Tumor weight (g) 2.2± 0.2 1.0± 0.2 *
Tumor volume (mm3) 7.2± 1.0 4.4± 0.4 *
Metastasis number (n) 10± 1.0 7.0± 0.8 *
Latency time (days) 15± 2.0 22± 1.0 *
 
Figure 4.1: Tumor parameters comparison between corn- and chia oil-fed mice.  
a) Tumor incidence was considered as the number of mice with tumors (n). Tumor weight 
was measured using a precision scale (g). Tumor volume was calculated using a digital 
caliper (mm3). The number of macroscopic metastases was recorded in all organs (n). 
Latency was determined as the time between tumor induction and detection of palpable 
tumors (days). Values are means ± SEM.; n=17-20. Corn vs. chia. t-Test, *p ≤ 0.05. b) 
Representative images of lung metastasis of hematoxylin/eosin stained tissues from corn 
and chia oil-fed mice.  (4x and 10x magnifications, scale bar 100 µm). 
 
4.2. ALA-enriched diet enhances apoptosis while lowering mitosis 
Given that an imbalance between cell proliferation and apoptosis may 
contribute to tumor progression (Liu et al, 2001), we evaluated apoptosis and 
mitosis in tumor tissues from ChO- and CO-fed mice stained with hematoxylin 
and eosin. We found that TUNEL positive cells (as an index of apoptosis) 
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significantly increased in tumor tissue from ChO-fed mice compared to the CO-
group (31.49 ± 0.57 vs. 17.59 ± 2.60 cell/mm2, p<0.05, n=3) (Figure 4.2, a). 
Consistently, we also found that Ki-67 positive cells (as an index of mitosis) were 
lower in ChO-fed mice with respect to CO-fed mice (89.88 ± 16.07 vs. 155.17 ± 
20.34 cell/mm2, p<0.05, n=3), indicating that cell proliferation was lower in tissues 
from ChO-fed mice (Figure 4.2, b). These findings are in accordance with the 
smaller tumor size found in mice receiving ChO-diet with respect to controls.  
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Figure 4.2: TUNEL and Ki-67 assay in tumor tissues of corn- and chia oil-fed mice.  
a) Apoptosis evaluation in primary tumor section tissues by TUNEL Assay. TUNEL-
positive cells in the nuclei are stained in red and total nuclei are stained with DAPI in blue 
(40x magnification, scale bar 10 µm). Bars show TUNEL-positive cells expressed as 
mean ± SEM/mm2. Corn vs. chia. t- Test. *p ≤ 0.05.  Experiments were repeated in tumor 
tissue sections from 3 mice for each dietary condition. b) Mitosis evaluation in primary 
tumor section tissues by Ki-67 assay. Ki-67-positive cells are stained in brown (40x 
magnification, scale bar 10 µm). Bars show Ki-67-positive cells expressed as mean ± 
SEM/mm2. Corn vs. chia. t-Test. *p ≤ 0.05 Experiments were repeated in tumor tissue 
sections from 3 mice for each dietary condition. 
 
4.3. ALA-enriched diet decreases tumor-angiogenesis 
Since vascular endothelial growth factor (VEGF) is a potent angiogenic 
factor with a major role in different steps of angiogenesis, we evaluated VEGFR-2 
expression in tumor tissues from ChO- and CO-fed mice by 
immunohistochemistry. We found that the number of vessels was significantly 
lower in tumor tissues from animals fed ALA-rich diet with respect to controls 
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(48.9 ± 17.88 vs 146.4 ± 22.24 vessel/mm2, p<0.05) (Figure 4.3). A large body of 
evidence indicates that the VEGF-VEGF receptor (R) complex, in particular 
VEGFR-2, is involved in the pathological angiogenesis promoting the malignancy 
of solid tumors. Therefore, it is possible to infer that reduced tumor size was 
influenced by a lower vascularization. 
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Figure 4.3: Effects of corn- and chia- oil diet on tumor angiogenesis.  
Vessel formation was evaluated in tumors tissues from corn- or chia oil fed-mice. a) Bars 
show vessel density expressed as mean ± SEM/mm2. Corn vs. chia. t- Test. *p ≤ 0.05. 
Experiments were repeated in tumor tissue sections from three mice for each dietary 
condition..b) and c): microphotographs of VEGFR-2 immunostained tumor sections from 
corn- and chia-fed mice, respectively (40x magnification, scale bar 10 µm).  
 
Given these in vivo findings, we next studied whether Ȧ-3 PUFAs have 
direct anti-angiogenic actions on endothelial cells. In particular we used 
docosahexaenoic acid (ϊHA ββ:6, Ȧ-γ) a downstream metabolite from α-linolenic 
acid (ALA 18:γ, Ȧ-3). 
 
4.4. DHA and AA did not decrease endothelial cell viability 
In order to determine possible effects of PUFAs on endothelial cell 
viability, an MTT assay was performed. We found that HUVECs were maximally 
viable when treated with 1 to 50 µM DHA for 24h (Figure 4.4, a). Similar results 
were obtained in cells treated with 1 to 30 µM AA for 48h (Figure 4.4, d). 
Conversely, when cells were challenged with 50 µM DHA for 48h (65.3 ± 13.0% 
vs control, p<0.05) or 72h (42.7 ± 13.8% vs control, p<0.05) cell viability 
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significantly decreased (Figure 4.4, b and c). Overall, these data indicate that 
DHA concentrations up to 30 µM DHA were suitable to carry out further 
experiments since cell viability was not significantly affected. 
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Figure 4.4: Effects of DHA (ω-3) and AA (ω-6) on HUVEC viability after 24, 48 or 
72h. HUVECs were incubated for: a) 24, b) 48 or c) 72h with DHA (1-100 µM) or d) 48h 
with AA (1-50 µM) and cell viability was measured by MTT. Data are expressed as 
percent of untreated, control cells. Bars show the mean ± SEM of 3-4 independent 
experiments. Control vs. treatment. ANOVA, post hoc-test Dunnet. *p<0.05. 
 
4.5. DHA decreases endothelial cell migration (haptotaxis) in a time- and 
concentration-dependent manner 
In order to evaluate the effects of Ȧ-γ and Ȧ-6 PUFAs on integrin-
mediated non-directional motility of endothelial cells (haptotaxis), we used a 
wound healing migration assay in cells pre-treated with 1-30 µM DHA for 24-72h.  
As shown in Figure 4.5, we demonstrated that treatment with 30 µM DHA for 24h 
significantly decreased EC migration (-25% ± 6.8%, p<0.01) (Figure 4.5, a) when 
compared to untreated control cells taken as 100%. After 48h, 10 or 30 µM DHA 
significantly reduced endothelial cell migration (-20% ± 1.54% and -44% ± 8.9%, 
p<0.001, respectively) (Figure 4.5, b). Finally, 72h pre-treatment with increasing 
(1-30 µM) DHA concentrations significantly reduced cell migration with respect to 
67 
 
controls (Figure 4.5, c). Overall, DHA decreases ECs migration in a time-
concentration fashion.  
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Figure 4.5: Effect of DHA on HUVEC migration (haptotaxis) after 24, 48 or 72h.  
HUVECs were pre-treated with 1-30 µM DHA for: a) 24, b) 48 or c) 72h. Thereafter, 
monolayers were wounded (t0), and treated as above for 16h (t16). For each 
experimental condition, 3 micrograph images were taken at t0 and t16; wound closure 
was calculated as described in Methods. Bars show the mean ± SEM of 3 independent 
experiments. Control vs. DHA.  Control vs. treatment. ANOVA, post hoc-test Dunnet. 
*p<0.05; **p<0.01; ***p<0.001.  
 
4.6. DHA in the presence of ASA decreases endothelial cell migration 
(haptotaxis) without affecting viability 
We further analyzed the effect of COX-2 acetylated by aspirin in presence 
of DHA on EC migration by the wound healing assay. Differently from treatment 
with DHA alone, treatment with 10 µM DHA in presence of 50 µM aspirin (ASA) 
significantly inhibited EC migration (-36% ± 5.4%, p<0.001) already after 24h 
(Figure 4.6) while 10 µM AA in the presence of ASA did not induce any effect. 
Neither ASA nor AA alone affected EC migration as evaluated by the wound 
healing assay. In order to determine the cytotoxic effects of ASA alone or in 
presence of DHA,  ECs were challenged with increasing concentrations of ASA 
(10-100 µM) in the presence or absence of 10 µM DHA and the viability test was 
performed. HUVECs were maximally viable when treated with these compounds 
for 24h (Figure 4.6, c). 
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These data suggest that aspirin-acetylated COX-2 metabolites decreased 
endothelial cell migration by enhancing the anti-angiogenic effects of Ȧ-3 PUFAs 
without affecting cell viability. 
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Figure 4.6: Effect of DHA±ASA on HUVEC migration and viability after 24h. 
a) Representative images of a wound healing experiment in hematoxylin and eosin 
stained cells (4x magnification, scale bar 500 µm). b) HUVECs were pre-treated with 10 
µM DHA, 50 µM ASA or 10 µM DHA + 50 µM ASA for 24h, wounded (t0), and treated as 
above for 16h (t16). For each experimental condition, 3 micrograph images were taken at 
t0 and t16; wound closure was calculated as described in Methods.  Bars show the mean 
± SEM of 4 independent experiments. Control vs. treatment.  ANOVA, post hoc-test 
Dunnet, ***p<0.001. c) HUVECs were incubated for 24h with ASA (10-100 µM) or 10 µM 
DHA + ASA (10-100 µM) and cell viability was measured by MTT assay. Bars show the 
mean ± SEM of 3 independent experiments performed in quadruplicate. Data are 
expressed as % of control. Control vs. treatment. ANOVA, post hoc-test Dunnet.  
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Figure 4.7: Effect of AA in presence or absence of ASA on HUVEC migration after 
24h. a) Representative images of a wound healing experiment in hematoxylin and eosin 
stained cells (4x magnification, scale bar 500 µm). HUVECs were pre-treated with 10 µM 
AA, 50 µM ASA or 10 µM AA + 50 µM ASA for 24h, wounded (t0), and treated as above 
for 16 h (t16). For each experimental condition, 3 micrograph images were taken at t0 
and t16; wound closure was calculated as described in Methods. Bars show the mean ± 
SEM of 3 independent experiments. Control vs. treatment.  ANOVA, post hoc-test 
Dunnet. 
 
Moreover, when HUVECs were challenged with DHA+ASA for 48h 
(Figure 4.8, a and b) or 72h (Figure 4.9, a and b) the inhibitory effect on cell 
migration was accentuated (-44 ± 4.9% and -53 ± 1.2%, p<0.001, respectively).  
Viability of treated cells was not different with respect to control cells at any time 
or concentration tested (Figure 4.8, c and 4.9 c). Differently from what observed 
for DHA, pre-treatment of HUVECs with AA in presence of ASA for 48h did not 
affect cell migration (Figure 4.10, a). Cell viability was also similar with respect to 
control (Figure 4.10, b). Overall, DHA in presence of ASA enhances its 
antiangiogenic capabilities and this effect is unrelated to cell proliferation. These 
data suggest a possible role for metabolites from ASA-acetylated COX-2 in 
endothelial cell migration.  
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Figure 4.8: Effect of DHA±ASA on HUVEC migration and viability after 48h.  
a) Representative images of a wound healing experiment in hematoxylin and eosin 
stained cells (4x magnification, scale bar 500 µm). b) HUVECs were pre-treated for 48h 
with 10 µM DHA, 50 µM ASA or 10 µM DHA + 50 µM ASA, wounded (t0), and treated as 
above for 16h (t16).. For each experimental condition, 3 micrograph images were taken 
at t0 and t16; wound closure was calculated as described in Methods.  Bars show the 
mean ± SEM of 3 independent experiments. Control vs. treatment.  ANOVA, post hoc-test 
Dunnet. *p<0.05; ***p<0.001. c) Cells were incubated for 24h with ASA (10-100 µM) or 10 
µM DHA + ASA (10-100 µM) and cell viability was measured by MTT assay. Bars show 
the mean ± SEM of 3 independent experiments performed in quadruplicate. Data are 
expressed as % of control. Control vs. treatment. ANOVA, post hoc-test Dunnet. 
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Figure 4.9: Effect of DHA±ASA on HUVEC migration and viability after 72h. 
 a) Representative images of a wound healing experiment in hematoxylin and eosin 
stained cells (4x magnification, scale bar 500 µm). b) HUVECs were incubated for 72h 
with 10 µM DHA, 50 µM ASA or 10 µM DHA + 50 µM ASA, wounded (t0), and treated as 
above for 16h (t16). For each experimental condition, 3 micrograph images were taken at 
t0 and t16; wound closure was calculated as described in Methods.  Bars show the mean 
± SEM of 3 independent experiments. Control vs. treatment. ANOVA, post hoc-test 
Dunnet. ***p<0.001. c) Cells were incubated for 24h with ASA (10-100 µM) or 10 µM DHA 
+ ASA (10-100 µM) and cell viability was measured by MTT assay. Bars show the mean 
± SEM of 3 independent experiments performed in quadruplicate. Data are expressed as 
% of control. Control vs. treatment. ANOVA, post hoc-test Dunnet. 
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Figure 4.10: Effect of AA±ASA on HUVEC migration and viability after 48h.  
a) HUVECs were pre-treated with 10 µM AA, 50 µM ASA or 10 µM AA + 50 µM ASA for 
48h, wounded (t0), and treated as above for 16h (t16) with the same treatment. For each 
experimental condition, 3 micrograph images were taken at t0 and t16; wound closure 
was calculated as described in Methods. Bars show the mean ± SEM (%) of 3-4 
independent experiments. Control vs. treatment. ANOVA, post hoc-test Dunnet. b) Cells 
were incubated for 48h with ASA (10-1000 µM) or 10 µM AA + ASA (10-1000 µM) and 
cell viability was measured by MTT assay. Bars show the mean ± SEM of 3 independent 
experiments performed in quadruplicate. Data are expressed as % of control. Control vs. 
treatment. ANOVA, post hoc-test Dunnet.  
 
4.7. 17R-HDHA decreases endothelial cell migration (haptotaxis) without 
affecting viability 
In order to assess the role of DHA metabolites from acetylated COX-2 in 
cell migration, we tested the anti-angiogenetic capability of 17R-HDHA. We found 
that after 24h pre-treatment, 1 and 3 µM 17R-HDHA decreased EC migration (-
12% ± 4.1% and -28% ± 1.9%, p<0.01, respectively) (Figure 4.11, b). Moreover, 
this effect was higher after 48h (-22% ± 3.7% and -37% ± 7.4%, p<0.01, 
respectively) (Figure 4.11, a and c), without affecting EC viability at any time or 
concentration tested (Figure 4.11, d). These data support an effect of 17R-HDHA 
diminishing EC migration towards a gradient of cell adhesion sites. 
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Figure 4.11: Effect of 17R-HDHA on HUVEC migration and viability. 
a) Representative images of a wound healing experiment in hematoxylin and eosin 
stained cells  after 48h treatment (4x magnification, scale bar 500 µm). HUVECs were 
pre-treated with 100 and 300 nM or 1 and 3 µM 17R-HDHA for a) 24h or b) 48h, wounded 
(t0), and treated as above for 16h (t16). For each experimental condition, 3 micrograph 
images were taken at t0 and t16; wound closure was calculated as described in Methods.  
Bars show the mean ± SEM of 3 independent experiments. Control vs. treatment. 
ANOVA, post hoc-test Dunnet. *p<0.05; **p<0.01. d) Cells were incubated for 48h with 
100 nM-3 µM 17R-HDHA and cell viability was measured by MTT assay. Bars show the 
mean ± SEM of 3 independent experiments performed in quadruplicate. Data are 
expressed as % of control. Control vs. treatment. ANOVA, post hoc-test Dunnet. 
 
4.8. 17R-HDHA decreases endothelial cell migration (chemotaxis) in a 
concentration-dependent manner 
Chemotaxis assays are useful to measure HUVEC migration in response 
to an attractant gradient, an essential step in tumor angiogenesis. In order to 
investigate the role of 17R-HDHA on EC migration in response to a chemical 
stimulus at shorter time points, we used a microchemotaxis chamber. Already 
after 6h, 17R-HDHA (300 nM, 1-3 µM) reduced FBS-induced EC migration (-
19.5% ± 1.4%, -30% ± 4.0% and -64% ± 3.5%, respectively; **p<0.01 and 
***p<0.001,) (Figure 4.12, a and b), while DHA alone did not show any effect 
(data not shown). 
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Figure 4.12: Effect of 17-R HDHA on HUVEC chemotaxis. HUVEC migration toward 
15% FBS (control) was measured in a microchemotaxis chamber in the presence of 
increasing concentration of 17R-HDHA (300 nM-3 µM).  a) Representative images of 
migrated cells on the bottom of the filter membrane as detailed in Methods. Migrated cells 
were counted under a light microscope (20x magnification, scale bar 100 µm). b) Bars 
show the mean ± SEM of 3 independent experiments performed in sextuplicate and 
expressed as % of control. Control vs. treatment. ANOVA, post hoc-test Dunnet. 
**p<0.01; ***p<0.001. 
 
4.9. DHA in presence of ASA or 17R-HDHA decrease capillary tube-like 
formation 
We further analyzed the effect of 17R-HDHA on tubularization, the 
process of organization of endothelial cells in capillary tube-like structures when 
cultured onto extracellular matrix proteins. To determine whether cells treated 
with 10 µM DHA in the presence of 50 µM ASA or 17R-HDHA at concentrations 
300 nM or 3 µM affected the formation of capillary-like structures, we used a 
Matrigel® assay. 
Qualitative analysis of imagines shows decreased formation of capillary-
like structures in ECs treated with either 10 µM DHA in the presence of 50 µM 
ASA or 17R-HDHA for 6h (Figure 4.13).  
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Figure 4.13: Effect of 10 µM DHA in the presence of 50 µM ASA or 17R-HDHA on 
HUVEC capillary tube-like formation. Representative phase contrast microphotographs 
showing the effect of: a) control b) 10 µM DHA in the presence of 50 µM ASA, c) 300 nM 
17R-HDHA and d) 3 µM 17R-HDHA on HUVECs cultured onto Matrigel® for 4h (40x 
magnification, scale bar 200 µm). 
 
 
 
Figure 4.14: Schematic representation of parameters used for the quantitative 
analysis. 
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Moreover, quantitative analysis (Figure 4.15) of topological parameters 
(number of nodes, junctions, meshes and total mesh area, see figure 4.14) 
shows that 10 µM DHA in the presence of 50 µM ASA (-33 ± 11%, p<0.05) as 
well as 300 nM and 3 µM 17R-HDHA (-30% ± 9.6% and -32% ± 2.8%, p<0.05, 
respectively), decreased node formation (Figure 4.15, a). The number of 
junctions showed a tendency to decrease but the difference was not significant 
with respect to control cells (Figure 4.15, b). Meshes (Figure 4.15, c) as well as 
meshes area (Figure 4.15, d) significantly decreased in treated compared to 
control cells. As for dimensional parameters (total tubule length), no significant 
differences were observed in treated ECs with respect to controls (Figure 4.15, 
e). These data demonstrate that DHA in presence of ASA as well metabolites 
from acetylated COX-2 exerted an anti-angiogenic effect by decreasing capillary 
tube-like formation.  
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Figure 4.15: Effect of 10 µM DHA in the presence of 50 µM ASA and 17R-HDHA on 
HUVEC capillary tube-like formation. Quantitative analysis of the effect of 10 µM DHA 
in the presence of 50 µM ASA and 17R-HDHA on topological parameters: a) number of 
nodes, b) junctions, c) meshes and d) mesh area; and on dimensional parameters: e) 
total length. After 6h incubation, 3 micrograph images/each experimental condition were 
taken. Bars show the mean ± SEM of 3 independent experiments. Data are expressed as 
% of control. Control vs. treatment. ANOVA, post hoc-test Dunnet. *p<0.05; **p<0.01.  
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4.10. DHA in the presence of ASA increases endothelial 17R-HDHA 
production.  
In order to demonstrate the ability of HUVEC to produce 17R-HDHA, we 
analyzed the supernatants of cells pre-treated with DHA (10 µM), ASA (50 µM) or 
DHA (10 µM) in presence of ASA (50 µM) for 24 hours by liquid chromatography-
tandem mass spectrometry. We demonstrated that HUVECs treated with DHA in 
presence of ASA produced higher amounts of 17R-HDHA with respect to cells 
treated with DHA alone (Figure 4.16). These data suggest that ECs treated with 
aspirin in the presence of DHA are able to synthesize 17R-HDHA. 
 
4,36 ng/700µL
DHA 
(10µM)
a)
0 ng/700µL
ASA 
(50µM)
b)
10,10 ng/700µL
DHA+ASA
c)
 
 
Figure 4.16: Synthesis of 17R-HDHA in HUVECs treated with DHA, ASA or 
DHA+ASA. Cell supernatants were analyzed using LC-MS/MS. Representative MS 
spectrum of 17R-HDHA from HUVECs incubated for 24h with a) 10 µM DHA, b) 50 µM 
ASA and c) 10 µM DHA in the presence of 50 µM ASA. In the right graph, added 17R-
HDHA was used as a standard (retention time: 3.38 min).  
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5. DISCUSSION 
 
This research began in Argentina where mice were fed a diet based on 
chia (Salvia hispanica L) seeds oil (ωhO diet) as a source of α-linolenic acid 
(ALA18:γ, Ȧ-3). The first specific aim was to determine the anti-growth and 
antiangiogenic effects of a ChO diet on a syngeneic mouse model of breast 
cancer (BC). The second specific aim was to investigate the role of metabolites 
from aspirin (ASA)-acetylated COX-2 in the presence of either docosahexaenoic 
acid (ϊHA ββ:6, Ȧ-3), a downstream product of ALA, or arachidonic acid (AA 
β0:4, Ȧ-6), in several in vitro models of angiogenesis. Ex vivo and in vitro 
angiogenesis experiments have been carried out in Italy. 
We showed reduced tumor growth parameters in mice fed the ALA-
enriched diet. The direct route through which Ȧ-3 PUFAs are hypothesized to act 
in tumor cells is via incorporation into cell membranes (Turk et al, 2013). 
Vegetable oils with more than 50% of ALA in their composition such as rosa 
canina, sacha inchi and chia oil are good sources of Ȧ-3 PUFAs. Recent studies 
performed in rodents fed vegetable oils have shown that ALA can be converted 
to DHA in organs such as liver and brain (Valenzuela et al, 2014). Moreover, it 
has been demonstrated that an ALA-rich diet increases the level of ALA and its 
downstream metabolites, such as eicosapentaenoic acid (EPA β0:5, Ȧ-3) and 
DHA, in tumor tissues (Mason et al, 2015; Espada et al, 2007). Thus, physical-
chemical alterations of the lipid microenvironment may affect the structural and 
functional properties of membranes, thereby altering the growth characteristics of 
neoplastic cells (Corsetto et al, 2012). An indirect possible route through which 
Ȧ-3 PUFAs are hypothesized to act is related to their metabolic conversion into 
bioactive metabolites. An important mechanism for the health-promoting effects 
of Ȧ-3 PUFAs is the suppression of prostanoid generation derived from the 
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metabolism of linoleic acid (LA 18:β, Ȧ-6) and AA, which in turn might be involved 
in cell growth, apoptosis, angiogenesis and metastasis.   
In particular, it has been demonstrated that EPA and DHA inhibit the 
formation of Ȧ-6 lipid mediators via multiple mechanisms, including reduced 
release of AA from membrane phospholipids, inhibition of the enzymatic activities 
of metabolizing enzymes and direct competition with AA for enzymatic 
conversions. AA, EPA and DHA also serve as alternative substrates of lipid 
metabolism enzymes, leading to increased formation of Ȧ-3 lipid mediators 
(Wang et al, 2014). In particular, 13(S)-HODE (produced from LA metabolism by 
15-LOX) is associated with rapid proliferation, aggressive grade and metastases 
in breast cancer (O'Flaherty et al, 2013).  
We evaluated the effects exerted by a ChO-diet enriched in ALA on tumor 
cell proliferation and apoptosis. We found that Ki-67-positive cells were less 
abundant in mammary tumors from mice fed the ChO-diet compared to control 
mice (fed corn oil diet, enriched in LA), whereas the number of TUNEL-positive 
cells significantly increased. The effects on tumor cell growth observed in ChO-
fed mice could be explained, at least in part, by changes in the lipid composition 
of membrane microdomains, which in turn may lead to the downregulation of 
growth factor receptors such as epidermal growth factor receptors (EGFR, HER-
2) involved in BC growth (Corsetto et al, 2011). Our data are in line with 
previously published data obtained in animal fed different Ȧ-3 enriched diets. In 
particular, dietary intake of ALA from flaxseed has been shown to suppress 
breast tumor growth in ovariectomized athymic BALB/c mice (Chen et al, 2007). 
In addition, previously published data from the Argentinian lab demonstrated that 
ALA-rich diets based on mystol or perilla oils reduced mammary tumor growth 
(Muñoz et al, 1995; Nakamaya et al, 1993). In vitro data support an anti-
proliferative and pro-apoptotic role of ALA in several cell lines. In particular, ALA 
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upregulates Bax expression (pro-apoptotic) and downregulates Bcl-2 (anti-
apoptotic) expression in a dose-dependent manner in an ER-positive breast 
cancer cell line (Kim et al, 2009). This finding suggests that ALA mediates 
growth-inhibitory and pro-apoptotic effects in estrogen-positive breast cancer 
cells.  
Angiogenesis is a tightly regulated process that contributes to tumor 
growth and metastasis (Potente et al, 2011). A large body of evidence indicates 
that the vascular endothelial growth factor (VEGF)-VEGF-receptor (VEGFR) 
complex, in particular VEGFR-2, is involved in pathological angiogenesis, which 
promotes the malignancy of solid tumors. Moreover, VEGFR-2 targeted therapy 
was demonstrated to restore the abnormal vasculature in tumors, enhancing their 
susceptibility toward conventional therapy (Kampen, 2012). In order to determine 
the effect of Ȧ-3 PUFAs in tumor angiogenesis, we evaluated VEGFR-2 
expression in primary tumor sections from animals fed ChO- and control diets. In 
our model, the vessel number was significantly lower in tumor tissues from 
animals fed the ALA-rich diet with respect to controls. These data suggest that 
the reduced tumor size observed in ChO-fed mice could also be due to impaired 
vascularization. Although several in vivo studies showed that Ȧ-3 PUFAs inhibit 
angiogenesis (Spencer et al, 2009), this is the first evidence for an antiangiogenic 
effect of a ChO diet as a source of ALA. In particular, a study carried out in a 
murine model of breast cancer showed that a Ȧ-3-rich diet inhibited primary 
mammary tumor growth through the modulation of specific determinants of 
vascularization, such as CD31 and VEGF (Mukutmoni-Norris et al, 2000). It has 
also been demonstrated that fish oil-fed rats inoculated with a highly metastatic 
cell line display decreased microvessel density along with decreased metastasis, 
suggesting that angiogenesis contributes to the anti-metastatic effect of dietary 
Ȧ-3 PUFAs (Mannini et al, 2009). In addition, in transgenic Fat-1 mice (able to 
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convert Ȧ-6 to Ȧ-3 PUFAs) inoculated with a lung cancer cell line, tumor growth 
and angiogenesis were significantly diminished compared to wild-type mice 
(Taguchi et al, 2014). Moreover, it has been shown that VEGF circulating blood 
levels are reduced in individuals with lower serum Ȧ-6 PUFAs/Ȧ-3 PUFAs ratio 
(due to higher Ȧ-γ PUFA levels), with respect to individuals with higher Ȧ-6 
PUFAs/Ȧ-3 PUFAs ratio (Ambring et al, 2006). 
Starting from in vivo data by our group and others supporting a role for Ȧ-
3 PUFAs in decreasing tumor-angiogenesis, we next investigated whether Ȧ-3 
PUFAs have direct anti-angiogenic actions on human endothelial cells. In 
particular, we used ϊHA (ββ:6, Ȧ-γ), a downstream metabolite of ALA (18:γ, Ȧ-
3). We compared the effects of DHA with those of AA (β0:4, Ȧ-6). Interestingly, in 
mammals DHA is found predominantly in neural tissue, where it may constitute 
up to 25-35% of the total membrane acyl chains (Strokin et al, 2004). Therefore, 
in order to test specific effects in endothelial cells, DHA has to be added 
exogenously. 
Several in vitro and in vivo studies have shown that DHA decreases, while 
AA promotes angiogenesis (Kang and Liu, 2013; Zhang et al, 2013). However, 
compared to specific AA-derived metabolites, less data are available on the role 
of DHA metabolites (Wang et al, 2014). In particular, it has been recently 
demonstrated that acetylated COX-β in presence of either AA or Ȧ-3 PUFAs 
generates several metabolites from DHA including 17R-HDHA (Serhan, 2015). 
Interestingly, metabolites produced in vivo by Ȧ-3 PUFAs have potent anti-
inflammatory effects and, considering that inflammation can stimulate 
angiogenesis, it is conceivable that reduced inflammation modulates 
angiogenesis in vivo. However, although the ability of metabolites from ASA-
acetylated COX-2 to promote the resolution of inflammation is well recognized, 
their direct role in angiogenesis is almost unexplored (Serhan, 2015).  
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First, we assessed the effects of PUFAs on endothelial cell viability. We 
found that human umbilical vein endothelial cells (HUVECs) were viable when 
treated with ϊHA at concentrations up to γ0 μM for β4 to 7β hours. Similarly, in 
HUVECs challenged with AA, no effects on HUVEC viability were observed in the 
concentration range 10-50 μM after treatment for up to 48h. Thereafter, we tested 
cell viability on EC challenged with 10 µM DHA (24-72h) or 10 µM AA (48h) in 
presence of acetylsalicylic acid (ASA) or with ASA alone (10 µM – 1 mM); also in 
this case cell viability did not differ with respect to controls. Consistently, 
Szymczak et al. (2008) treated HUVECs with DHA or AA at concentrations up to 
160 μM for β0h, and observed that cell viability decreased only when PUFA 
concentrations exceeded 40 µM. Similarly, in the human microvascular 
endothelial cell line HMEC-1 co-treated with VEGF (β0 ng/mL) and 50 μM ϊHA 
for 48h, cell viability decreased with respect to control cells (Zhuang et al, 2013). 
In contrast, other authors showed no adverse effects on cell growth by 100 μM 
DHA in the presence or absence of VEGF (50 ng/mL) (Chao et al, 2014). In an in 
vitro study aimed to investigate whether ASA interferes with the proliferative 
stage of angiogenesis, the authors found that treating HUVECs with 0.01-0.10 
mM ASA for 24h did not change cell proliferation. However, treatment with 1 mM 
ASA inhibited HUVEC proliferation at later time points (Pearce et al, 2003). 
Moreover, Borthwick et al. (2006) found that in a well-characterized 
microvascular cell line (HMEC-1) challenged with ASA (0.5-5 mM) no effects on 
cell proliferation were detectable with up to 0.5 mM ASA, whereas 2 and 5 mM 
ASA caused a significant decrease in cell viability after 48h. Overall, decreased 
proliferation and increased apoptosis have been reported as major effects of Ȧ-3 
PUFAs in cultured endothelial cells as well as in other cells. However, some of 
these effects may be due to lipid peroxidation promoted by high PUFA 
concentrations (100-300 µM) (Artwohl et al, 2004). The present study was 
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performed using PUFA concentrations (10-30 µM) that do not affect cell 
proliferation in order to avoid effects on the proliferative stage of angiogenesis. 
Interestingly, a recent paper demonstrated that incorporation of DHA in cell 
membranes of rat cardiomyocytes challenged with β5 μM ϊHA approximates the 
incorporation levels reached after treating rats with a diet corresponding to about 
4 g total Ȧ-3/day (Lamaziere et al, 2015). This dietary intake is likely to 
correspond to that provided by supplementation with recommended dose in 
humans (Shearer et al, 2012).  
We further analyzed endothelial cell migration, which represents an 
important step of angiogenesis. Cell migration requires tight regulation of the cell 
contractile and non-contractile states as well as integration of signals elicited by 
haptotactic and chemotactic stimuli (Lamalice et al, 2007). We first performed 
wound healing assays in order to evaluate endothelial cell haptotaxis, a process 
of cell migration activated in response to integrins binding to extracellular matrix 
(ECM) components (Lamalice et al, 2007). We observed a significantly 
decreased cell migration in HUVECs pre-treated with 30 µM DHA for 24h. At later 
time points (48 or 72 h), endothelial cells migration was significantly and to a 
greater extent reduced in cells challenged with lower DHA concentrations (10 
µM) with respect to controls. Overall, DHA decreased HUVEC migration in a 
time- and concentration-dependent fashion. A recent study demonstrated that in 
the HMEC-1 cell line treatment with 50-100 μM ϊHA for β4 h inhibits wound 
closure by up to 30% (Zhuang et al, 2013). As noted above, DHA decreases 
while AA promotes angiogenesis (Kang and Liu, 2013). Recently, Chao et al. 
(2014) demonstrated that 8h treatment with 100 µM DHA inhibits VEGF-induced 
cell migration via binding to G-protein coupled receptor 120 (GPR120), inhibition 
of extracellular-signal-regulated kinases (ERK1/2) and endothelial nitric oxide 
synthase (eNOS) phosphorylation, which is critical to cell migration. However, the 
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mechanisms underlying the inhibition of cell migration by DHA, which is critical for 
angiogenesis and wound repair, are not fully understood. The Ȧ-3 PUFAs,  act in 
part via formation of certain lipid metabolites (LMs) such as cyclooxygenase 
(COX)-derived prostaglandin E3 (PGE3) (Szymczak et al, 2008), lipoxygenase 
(LOX)-derived 4-hydroxy-docosahexaenoic acid (4-HDHA) (Sapieha et al, 2011), 
cytochrome P450 (CYP)-derived epoxydocosapentaenoic acids (EDPs) (Zhang 
et al, 2013), as well as unique Ȧ-3 lipid autacoids such as resolvins and 
protectins (Kang and Liu, 2013).  
It has been shown that several COX-1 and COX-2 AA-derived 
eicosanoids have a pro-angiogenic effect (Salvado et al, 2013; Nie et al, 2000; 
Pola et al, 2004). In particular, AA-derived PGE2 has been extensively studied in 
the context of tumor progression, including the angiogenic process. For example, 
AA-derived PGE2 augmented, whereas EPA (β0:5 Ȧ-3, a precursor of DHA)-
derived PGE3 suppressed growth factor-induced angiopoietin 2 synthesis, 
suggesting a beneficial effect of Ȧ-3 PUFAs in reducing angiogenesis (Szymczak 
et al, 2008). Moreover, pharmacological and gene silencing experiments have 
recently demonstrated that endothelial PGE2 biosynthesis is dependent on COX-
1, rather than COX-2, and plays a pivotal role in the formation of capillary-like 
structures (Salvado et al, 2013). Previously, other authors supported a role for 
PGE2 in angiogenesis (Greenhough et al, 2009; Namkoong et al, 2005). For 
example, a study demonstrated a role for TXA2, another metabolite generated 
from AA, in angiogenesis (Nie et al, 2000; Ashton et al, 2004). Conversely, the 
direct role of DHA metabolites in the setting of angiogenesis has been less 
investigated. However, generation of AA metabolites decreases when Ȧ-3 
PUFAs are added to the culture medium of endothelial cells. In particular, 
enrichment of bovine endothelial cells with DHA and EPA reduces their capacity 
to produce PGI2 (Hadjiagapiou et al, 1986; Hadjiagapiou et al, 1987), an AA 
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metabolite with angiogenic properties in vivo mediated through VEGF induction 
(Pola et al, 2004). 
Recent research showed a high degree of inter-individual variability in 
metabolizing Ȧ-γ PUFAs to generate LMs upon dietary intake of Ȧ-3 PUFAs. 
Clearly, it is important to elucidate the specific lipid metabolizing enzymes and 
metabolites required for the anti-tumor and anti-angiogenic effects of Ȧ-3 PUFAs. 
The identified enzymes and metabolites could serve, for example as biomarkers 
to screen the sub-populations which are most likely to respond to Ȧ-3 PUFAs, or 
develop personalized doses for Ȧ-γ supplementation. In addition, bioactive Ȧ-3 
LMs could serve as biotemplates to design more potent and safer therapeutic 
drugs. ωompared with the Ȧ-6 series LMs, the roles of Ȧ-3 series LMs in 
angiogenesis and cancer have been less investigated (Wang et al, 2014). 
Starting from this knowledge, we further investigated the role of DHA 
metabolites from aspirin-acetylated COX-2 in angiogenesis. We found that, when 
treating HUVECs with low DHA concentration (10 µM) in the presence of 50 µM 
ASA, differently from what observed with DHA alone, cell migration was 
significantly inhibited already after 24h. Moreover, in HUVECs challenged with 
low DHA concentration (10 µM) in the presence of 50 µM ASA for 48h or 72h the 
inhibitory effect on cell migration was accentuated. In contrast to what observed 
with DHA, when HUVECs were challenged with 10 µM AA in the presence of 
ASA, no effects on endothelial cell migration were observed after 24 or 48h. In 
addition, neither ASA nor AA alone affected EC migration as evaluated by the 
wound healing assay. These findings are partially in contrast with previously 
published data demonstrating that ASA-triggered lipoxins (AT-L, generated by 
acetylated COX-2 in the presence of AA) inhibit VEGF-induced EC migration in a 
concentration-dependent fashion (Fierro et al, 2002). In the latter study, however, 
the authors did not test the effects of AA in the presence of ASA on cell 
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migration, rather they directly evaluated the effect of AT-L. In our work, we did not 
observe any effect, probably because endogenous AT-L precursors are unstable. 
Future experiments with exogenous 15R-HETE could help address these 
discrepancies.  
It is widely recognized that, while COX-1 acetylated by ASA is 
permanently inactivated, acetylated COX-2 is still capable to metabolize PUFAs 
to a novel series of R-containing precursors that are specialized lipid mediators 
with pro-resolving activity (Dovizio et al, 2013; Serhan et al, 2002). In particular, 
acetylated COX-β in the presence of either AA or Ȧ-3 PUFAs generates several 
metabolites including 18R-HEPE from EPA and 17R-HDHA from DHA. These 
metabolites, after oxygenation by 5-LOX generally expressed by inflammatory 
cells such as neutrophils, generate ASA-triggered lipoxins (AT-L, from AA) or 
resolvins (AT-Rv D, from DHA) (Serhan et al, 2002). There is little evidence for 
the expression of 5-LOX by endothelial cells (Walker et al, 2002), and we were 
unable to detect this enzyme in HUVECs (unpublished data). Overall, based on 
results in HUVECs treated with DHA and ASA, we hypothesize that aspirin-
acetylated COX-2 metabolites decreased endothelial cell migration by enhancing 
the anti-angiogenic effects of Ȧ-3 PUFAs.  
We found that pre-treating HUVECs with 17R-HDHA (1 and 3 µM) for 24h 
decreased EC migration as evaluated by the wound healing assay, and this 
effect further increased after 48h treatment. We found no significant effect on cell 
viability using 17R-HDHA up to 3 µM for 48h. Next, we evaluated the effect of 
17R-HDHA on EC migration in response to FBS (containing a mixture of growth 
factors). Already after 6h, 17R-HDHA (300 nM-3 µM) reduced HUVEC migration 
in a dose-dependent manner, while DHA alone did not show such short-term 
effect (data not shown). These data are compatible with the production of 
bioactive metabolites from DHA, and strongly support a role for DHA metabolites 
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generated by ASA-acetylated COX-2 in inhibiting endothelial cell migration. To 
further explore the role of 17R-HDHA, we tested whether treatment with 10 µM 
DHA in the presence of 50 µM ASA or with 17R-HDHA alone affected the 
formation of capillary-like structures by endothelial cells when cultured on 
extracellular matrix proteins. We found that 10 µM DHA in the presence of 50 µM 
ASA as well as exogenously added 17R-HDHA decreased the ability of 
endothelial cells to organize into capillary-like structures, strongly supporting a 
role for this metabolite in the above-described effects. 
Finally, we analyzed the ability of HUVEC to produce 17R-HDHA 
endogenously. The supernatants of HUVECs pre-treated with DHA (10 µM) or 
ASA (50 µM) or DHA plus ASA for 24h were analyzed by liquid chromatography-
tandem mass analysis. The data show that HUVECs treated with DHA in 
presence of ASA produced higher amounts of 17-HDHA with respect to cells 
treated with DHA alone. These results suggest that 17-HDHA mediates the 
antiangiogenic effects observed in cells treated with DHA in the presence of ASA. 
Unfortunately, we were not able to distinguish S- or R-containing isoforms, but 
since HUVECs do not express detectable mRNA levels of 15-LOX (Lee et al, 
2001), the enzyme capable of converting DHA to 17S-HDHA, we inferred that the 
17-HDHA detected was the isomer R. This is the first evidence demonstrating the 
endogenous production of 17-HDHA in non-stimulated human endothelial cells. 
The in vivo formation of 17-HDHA has been already demonstrated in 
different cells and tissues. Serhan and co-authors (2002) demonstrated that brain 
of aspirin-treated mice produces endogenous 17R-HDHA as do human microglial 
cells. Similarly, the same authors also demonstrated that in hypoxic HUVECs 
stimulated with inflammatory cytokines, COX-2 converted DHA to 13-hydroxy-
DHA that switched with ASA to 17R-HDHA. In addition, 17-HDHA has been 
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detected in a murine colitis model after treatment with ASA and DHA (Köhnke et 
al, 2013).  
Overall, our data support a role for DHA metabolites, in particular 17-
HDHA generated by ASA-acetylated COX-2, in inhibiting endothelial cell 
angiogenesis. We cannot exclude that high levels of Ȧ-3 PUFAs incorporated 
into cell membranes reduce angiogenesis through decreased production of pro-
angiogenic AA-derived eicosanoids. However, the basal production of 
prostanoids (except prostacyclin) in unstimulated endothelial cells is relatively 
low, and no detectable levels of other prostanoids have been found by liquid 
chromatography-tandem mass analysis (data not shown). Another mechanism 
that could, at least in part, explain the antiangiogenic effects of DHA in ASA-
treated endothelial cells involves COX-2 expression (Bolego et al, 2009). 
Previously published studies indeed reported that DHA can reduce COX-2 
expression in different cellular models (Song et al, 2014; Li et al, 2013). For 
example, it has been reported that in human saphenous vein endothelial cells 
(HSVECs) challenged with pro-inflammatory stimuli COX-2 expression and 
activity was reduced after 24h exposure to DHA, while COX-1 expression was 
not affected by DHA (Massaro et al, 2006). Moreover, DHA treatment of 
macrophages decreased LPS-induced PGE2 synthesis, primarily through 
reducing COX-2 expression (Li et al, 2013). Overall, these data support a role for 
DHA in reducing COX-2 expression in cells treated with inflammatory stimuli and 
provide a new explanation for some of the anti-inflammatory effects of DHA. 
Since the present work has been carried in the absence of any inflammatory 
stimulus, the modulation of unstimulated COX-2 expression is probably less 
relevant.  
To our knowledge, this is the first evidence for a role of DHA metabolites 
generated by ASA-acetylated COX-2, such as 17-HDHA as a precursor of AT-
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resolvins, in the setting of angiogenesis. Other authors demonstrated a functional 
role of these novel metabolites in different in vitro and in vivo models. For 
example, 17R-HDHA was recently shown to have anti-inflammatory properties in 
animal models of experimental colitis and arthritis (Lima-Garcia et al, 2011; Bento 
et al, 2011), while in vitro experiments showed that 17(R/S)-HDHA suppresses 
LPS-triggered tumor necrosis factor-α formation in a murine macrophage cell line 
(Weylandt et al, 2011). In addition, in the fat-1 transgenic mouse model, which 
endogenously forms Ȧ-γ PUFAs from Ȧ-6 PUFAs, lipidomic analyses of lipid 
mediators revealed significantly increased levels of 17-HDHA in the livers of mice 
carrying tumors with respect to controls, suggesting a possible role of this Ȧ-3 
PUFA-derived lipid mediator in suppressing liver tumorigenesis (Weylandt et al, 
2011). 
In addition, few data document the functional role of DHA-derived 
metabolites other than resolvin precursors in the setting of angiogensis. Recently, 
it has been demonstrated that epoxydocosapentaenoic acids (EDPs), which are 
lipid mediators produced by cytochrome P450 epoxygenases from DHA, inhibit 
VEGF and fibroblast growth factor 2-induced angiogenesis in vivo, and suppress 
endothelial cell migration and protease production in vitro via a VEGF receptor 2-
dependent mechanism (Zhang et al, 2013). Moreover, a key role for 4-HDHA (a 
metabolite from DHA by 5-LOX metabolism) has been described. 4-HDHA has 
potent effects in inhibiting endothelial cell proliferation and sprouting (Sapieha et 
al, 2011).  
To conclude, we found that in vivo an ALA-rich diet generates tumor-
microenvironmental changes resulting in an anti-growth effect in a murine breast 
cancer model. This effect is mediated, at least in part, by decreased tumor 
angiogenesis. This data supports a role for a chia oil diet, as an ALA dietary 
source, in the prevention and treatment of breast cancer. Moreover, we identified 
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a role for DHA metabolites derived from aspirin-acetylated COX-2 in vitro in 
inhibiting angiogenesis. Further experiments in animal models of tumor-
associated angiogenesis will shed more light on the potential beneficial direct 
effects of aspirin-triggered metabolites on angiogenesis and tumor growth. 
 
Limitations of the present work 
The present work was conducted on endothelial cell (EC) that can mimic 
individual steps of the angiogenic cascade, such as cell migration, proliferation 
and capillary-like formation. However, different cell types, such as fibroblasts, 
pericytes and smooth muscle cells, play a crucial role during new vessel 
formation by releasing soluble factors and establishing homotypic and heterotypic 
interactions. In addition, the interaction between HUVECs and extracellular matrix 
protein represents another critical step in the angiogenic process (Conway et al, 
2001). Although the molecular and cellular mechanisms of angiogenesis have 
been elucidated in vivo, the complexity of animal models often limits detailed 
mechanistic interpretation of experimental findings. A functional solution to bridge 
the gap between in vitro endothelial cultured cells and in vivo animal models is 
the use of ex vivo assays, in which vascular tissue explants are embedded in 
extracellular matrix gels and produce new vascular sprouts that differentiate in 
capillary-like structures such as rat and mouse aortic ring assays, frequently used 
to evaluate the efficacy of pro- and anti-angiogenic molecules (Seano et al, 
2013). Adaptations of this ex vivo assay may provide insights into the mechanism 
exerted by Ȧ-6 or Ȧ-3 PUFAs and their metabolites in the angiogenic process. 
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